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ABSTRACT	
INTERACTIONS	OF	THE	MURINE	CORONAVIRUS	MOUSE	HEPATITIS		
VIRUS	WITH	THE	TYPE	I	INTERFERON	RESPONSE	
LESTER	DILLON	BIRDWELL	
AND	
SUSAN	R.	WEISS	
Murine	 hepatitis	 virus	 (MHV)	 infection	 activates	 the	 potent	 antiviral	 oligoadenylate	
synthetase-endoribonuclease	latent	(OAS-RNase	L)	pathway	in	myeloid-derived	cells	of	
the	liver	and	brain	but	not	in	other	cell	types	in	these	organs.	Canonically,	it	is	thought	
that	upregulation	of	Oas	transcription	by	type	I	interferon	(IFN)	during	virus	infection	is	
needed	to	activate	the	pathway.	However,	MHV	induces	IFN	and	upregulate	OASs	only	
late	 in	 infection,	after	RNase	L	has	already	been	activated.	The	objective	of	 this	 thesis	
work	was	to	determine	what	role	interferon	and	OAS	play	in	RNase	L	activation.	For	this	
purpose,	bone	marrow	derived	macrophages	 (BMM)	were	used	 that	were	either	 fully	
competent	to	respond	to	and	secrete	IFN	(WT	B6),	unable	to	secrete	IFN	(Ifih1-/-),	or	not	
capable	 of	 IFN	 signaling	 (Ifnar1-/-).	 It	was	 found	 that	 basal	mRNA	 expression	 levels	 of	
Oas1a,	Oas2,	and	Oas3	 in	naïve	mice	were	 significantly	higher	 in	 the	 liver	 than	 in	 the	
brain	and	in	myeloid-derived	versus	non-myeloid	derived	cells.	Furthermore,	activation	
of	RNase	L	did	not	require	virus-induced	IFN,	but	rather	correlated	with	adequate	levels	
of	 basal	 Oas	 gene	 and	 protein	 expression,	 maintained	 by	 basal	 IFN	 signaling.	 This	
suggests	that	basal	 levels	of	OAS	might	 influence	the	host’s	ability	to	activate	RNase	L	
and	 restrict	 MHV	 infection	 in	 an	 organ-specific	 and	 cell	 type-specific	 manner.	 Data	
herein	 demonstrate	 that	 myeloid	 cells	 are	 pre-armed	 with	 high	 basal	 levels	 of	 OAS,	
sufficient	 to	allow	activation	of	RNase	 L	upon	 sensing	dsRNA	early	 in	 infection	before	
interferon	signaling	develops.	This	limits	virus	replication	and	spread,	thus	sparing	non-
myeloid	neighboring	cells	from	infection.	Together,	these	studies	have	helped	define	the	
increasingly	complex	interactions	between	MHV	and	the	type	I	IFN	response.		
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I	
CHAPTER	ONE	
	 INTRODUCTION	 	
I.1	 HISTORICAL	PERSPECTIVE	
Before	 2003,	 no	 severe	 human	 diseases	 were	 attributable	 to	 coronaviruses,	 lending	
little	 to	 their	 study.	While	 coronaviruses	have	been	described	 for	more	 than	50	years	
and	 their	 replication	 and	 pathogenesis	 have	 been	 actively	 studied	 since	 the	 1970s,	
coronaviruses	were	only	thought	to	cause	the	common	cold	in	humans	(Pelczar,	2010;	
Goldman,	 2010).	 However,	 some	 of	 the	 animal	 coronaviruses,	 such	 as	 porcine	
transmissible	 gastroenteritis	 virus	 (TGEV),	 bovine	 coronavirus	 (BCoV),	 and	 avian	
infectious	bronchitis	viruses	 (IBV)	are	of	veterinary	 importance	 (Saif,	2004).	There	had	
long	been	speculation	about	the	association	of	human	coronaviruses	with	more	serious	
human	diseases	 such	as	multiple	 sclerosis,	hepatitis,	and	enteric	disease	 in	newborns.	
None	 of	 these	 early	 associations	 had	 been	 substantiated	 until	 in	 2003,	 a	 new	human	
coronavirus,	 severe	 acute	 respiratory	 syndrome	 (SARS-CoV)	 was	 linked	 to	 a	 viral	
respiratory	disease	of	zoonotic	origin.	The	2002-2003	outbreak	of	SARS,	which	began	in	
southern	China,	 eventually	 involved	more	 than	8,000	persons	worldwide	and	was	 the	
first	human	coronavirus	to	cause	significant	disease	and	economic	repercussions	(Booth	
et	 al.,	 2003;	Dwosh	 et	 al.,	 2003;	Holmes,	 2003;	Ksiazek	 et	 al.,	 2003;	Lee	 et	 al.,	 2003;	
Peiris	et	al.,	2003b;	Poutanen	et	al.,	2003;	Tsang	et	al.,	2003;	Varia	et	al.,	2003;	WHO,	
2003;	De	Groot,	2013).	Another	more	deadly	coronavirus	new	to	humans	was	identified	
in	Saudi	Arabia	 in	2012	and	associated	with	Middle	East	 respiratory	syndrome	(MERS-
CoV).	As	of	2015,	sporadic	cases,	small	clusters,	and	large	outbreaks	of	MERS-CoV	have	
been	reported	 in	26	countries,	with	over	1600	cases	of	 the	virus	and	over	580	deaths	
(WHO,	2015).	The	occurrence	of	SARS-CoV	and	MERS-CoV,	which	caused	severe	and	life	
threatening	diseases,	 reclassified	coronaviruses	as	“emerging”	and	 ignited	research	on	
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these	esoteric	pathogens.	However,	SARS-CoV	is	classified	as	a	select	agent	defined	as	a	
biological	agent	that	has	been	determined	to	have	the	potential	to	pose	a	severe	threat	
to	 both	 human	 and	 animal	 health.	 Additionally,	 most	 work	 with	 MERS-CoV	 must	 be	
performed	 in	 either	 a	 Biosafety	 Level	 3	 (BSL-3)	 or	 an	 Animal	 BSL-3	 facility	 using	
respective	 work	 practices.	 Consequently,	 these	 viruses	 require	 specialized	 handling	
beyond	the	scope	of	many	laboratory	settings.	Therefore,	a	murine	coronavirus,	mouse	
hepatitis	 virus	 (MHV),	 has	 been	 used	 to	 study	 the	 pathogenesis	 and	 virulence	 of	
coronaviruses.	MHV	infects	several	organ	systems	in	laboratory	mice	providing	models	
for	 virus-induced	 acute	 encephalitis,	 hepatitis,	 pneumonitis,	 and	 gastroenteritis	 in	 a	
natural	host.	Moreover,	infections	with	MHV	provide	a	model	for	human	disease.	
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I.2	 VIRUS	CLASSIFICATION	AND	TAXONOMY	
The	name	"coronavirus"	 is	derived	from	the	Latin	corona,	meaning	crown	or	halo,	and	
refers	 to	 the	 characteristic	 appearance	 of	 virions	 under	 electron	 microscopy	 with	 a	
fringe	 of	 large,	 bulbous	 surface	 projections	 creating	 an	 image	 reminiscent	 of	 a	 royal	
crown	 or	 of	 the	 solar	 corona.	 Coronaviruses	 are	 part	 of	 Group	 IV	 of	 the	 Baltimore	
classification	system	and	are	enveloped	viruses	with	a	positive-sense	RNA	genome	that	
ranges	 from	 approximately	 26	 to	 32	 kilobases,	 extraordinarily	 large	 for	 an	 RNA	 virus.	
Coronaviruses	are	species	in	the	genera	of	virus	belonging	to	one	of	the	two	subfamilies	
Coronavirinae	 and	 Torovirinae	 in	 the	 family	 Coronaviridae.	 The	 Coronaviridae,	
Arteviridae,	 Roniviridae,	 and	Mesoniviridae	 families	 form	 the	 Nidovirales	 order.	 The	
order	Nidovirales	is	named	for	the	Latin	nidus,	as	all	viruses	in	this	order	produce	a	3'	co-
terminal	nested	set	of	subgenomic	mRNAs	during	infection	The	virus	that	has	the	largest	
known	nonsegmented	RNA	genome	of	31.5	kilobases,	MHV,	is	of	the	order	Nidovirales.	
MHV	is	a	prototypical	coronavirus	of	the	beta	genus.	Coronaviruses	are	divided	into	four	
genera	 (alpha,	 beta,	 gamma,	 and	delta).	 Betacoronaviruses	 include	 viruses	 that	 infect	
mice	and	rats	as	well	as	other	animal	species	and	humans	(Enjuanes,	2008;	Thiel,	2007;	
Balasuriya,	 2008;	 De	 Vries,	 1997).	MHV	 is	 a	 group	 of	 highly	 related	 strains	 causing	 a	
variety	of	diseases,	such	as	enteric	disease,	hepatitis,	and	respiratory	disease,	as	well	as	
encephalitis	and	chronic	demyelination.	(De	Groot,	2011;	ICTV,	2010).		
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I.3		 MOUSE	HEPATITIS	VIRUS	PATHOGENESIS	
Multiple	 strains	 of	 MHV	 exhibit	 different	 tropisms	 and	 levels	 of	 virulence.	 The	
commonly	 used	 laboratory	 strains	 such	 as	MHV-A59	 used	 herein	 infect	 primarily	 the	
liver	and	the	brain.	MHV-A59	 infection	of	mice	has	been	used	as	an	animal	model	 for	
studying	demyelinating	diseases,	such	as	multiple	sclerosis.	Other	strains	cause	enteric	
disease,	are	spread	easily	by	an	oral-fecal	route	in	animal	colonies,	and	are	a	particular	
danger	 to	 immunocompromised	 animals	 (Barthold,	 1993).	 MHV	 organ	 tropism	 and	
virulence	 is	dependent	on	 interactions	of	viral	proteins	and	host	 factors	and	 the	MHV	
model	 has	 been	 used	 extensively	 for	 investigating	 coronavirus-host	 interactions,	
including	elucidating	the	determinants	of	tissue	tropism	and	virulence.		
	
MHV-A59	strain	 is	a	 relatively	neuroattenuated,	moderately	hepatovirulent	strain	 that	
was	first	isolated	from	a	mouse	with	leukemia	in	1961	(Manaker	et	al.,	1961).	Although	
neuroattenuated	 compared	 to	 the	 more	 virulent	 MHV-JHM	 strain,	 A59	 causes	
demyelination	and	encephalomyelitis	(Lavi,	1984).	Central	nervous	system	(CNS)	disease	
induced	by	neurotropic	MHV	strains	is	divided	into	two	phases,	acute	encephalitis	and	
chronic	 demyelinating	 disease.	 Following	 intracranial	 or	 intranasal	 inoculation,	 MHV	
infects	 all	 major	 CNS	 cell	 types	 including	 neurons	 (the	 most	 frequently	 infected	 cell	
type),	glial	cells	(astrocytes,	oligodendrocytes,	and	microglia).		Typically,	viral	titers	peak	
five	 days	 after	 infection	 and	 begin	 to	 decline	 until	 infectious	 virus	 becomes	
undetectable	 approximately	 two	 weeks	 post	 inoculation	 (Leparc-Goffart	 et	 al.	 1998;	
Matthews	et	al.	2001;	Roth-Cross,	2008).	During	this	time,	infected	mice	develop	mild	to	
severe	encephalomyelitis,	characterized	by	infiltration	of	a	variety	of	inflammatory	cells	
into	 the	 brain	 and	 spinal	 cord.	 Innate	 immune	 responses	 are	 elicited	 and	 detectable	
within	 the	 first	 few	 days	 post	 infection.	 These	 early	 actions	 guide	 and	 inform	 the	
development	 of	 the	 adaptive	 immune	 response	 (Bergmann	 et	 al.,	 2006;	 Savarin	 and	
Bergmann,	2008),	including	the	involvement	of	CD8+	and	CD4+	T	cells.	CD8+	T	cells,	with	
the	 help	 of	 CD4+	 T	 cells,	 play	 a	 dominant	 role	 in	 controlling	 virus	 replication	 and	 are	
	 5		
	
most	numerous	in	the	brain	at	day	seven	post	infection,	coinciding	with	viral	clearance	
(Williamson	et	al.,	1991).	However,	despite	clearance	of	infectious	virus,	viral	RNA,	both	
genome	 and	mRNA,	 persist	 in	 the	 CNS	 and	 demyelination,	 largely	 immune-mediated,	
develops,	peaking	at	approximately	one	month	post	infection	(Elliott	et	al.,	2013;	Lavi	et	
al.,	1984;	Marten	et	al.,	2001).	Additionally,	other	adaptive	immune	mediators	such	as	B	
cells	enter	the	CNS	after	other	mediators	of	clearance	have	initiated,	so	B	cells	are	not	
required	 for	 this	 early	 process	 (Navas	 et	 al.,	 2001).	 However,	 B	 cell	 deficient	 mice	
experience	re-emergence	of	infectious	virus	in	the	CNS	(Matthews	et	al.,	2002).	Despite	
clearance	 of	 infectious	 virus,	 viral	 RNA	 persists	 in	 the	 CNS	 and	 immune-mediated	
demyelination	develops	and	peaks	around	four	weeks	post	infection.	Furthermore,	the	
degree	 of	 viral	 spread	 throughout	 the	 brain	 and	 spinal	 cord,	 tropism	 of	 virus	 for	
individual	CNS	cell	types,	and	dissemination	of	virus	to	other	organs	is	largely	dependent	
on	viral	strain	(Weiss	and	Navas-Martin,	2005).		
	
As	 stated,	 MHV-A59	 induces	 acute	 hepatitis	 in	 mice	 and	 serves	 as	 a	 model	 for	 the	
interactions	of	liver	cells	and	viruses	(Weiss	and	Leibowitz,	2011).	After	intrahepatic	(IH)	
inoculation	 of	 MHV-A59,	 viral	 replication	 is	 robust	 in	 the	 liver	 by	 three	days	 post	
infection	(dpi)	and	peaks	at	five	dpi;	inflammation,	or	hepatitis,	peaks	after	five	days	and	
is	mostly	cleared	by	seven	dpi	(Navas	et	al.,	2001;	Roth-Cross	et	al.,	2009).			
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I.4	 TYPE	I	INTERFERON	RESPONSE	
A	generic	host	defense	model	has	been	promulgated	for	over	a	century.	This	model	was	
strengthened	 after	 Elie	 Metchnikoff	 recognized	 and	 introduced	 the	 power	 of	
“phagocytes”	 to	 attack	 and	 destroy	 assaulting	 pathogens	 (Metchnikoff,	 1968).	
Furthermore,	 interferons	 (IFN)	 –	 a	 group	 of	 signaling	 proteins	made	 and	 released	 by	
host	 cells	 in	 response	 to	 the	 presence	 of	 several	 pathogens,	 including	 viruses	 –	were	
discovered	in	1957,	more	than	58	years	ago,	by	Alick	Isaacs	and	Jean	Lindenmann	when	
their	 experiments	 on	 influenza	 virus	 and	 viral	 interference	 revealed	 that	 an	 antiviral	
factor	could	“interfere”	with	viral	replication.	This	ability	is	attributable	to	IFNs	as	they	
belong	 to	 a	 large	 class	 of	 proteins	 known	 as	 cytokines	 that	 are	 molecules	 used	 for	
communication	between	cells	to	trigger	the	protective	defenses	of	the	immune	system	
that	 help	 eradicate	 pathogens	 (De	Andrea,	 2002;	 Cohen,	 2001).	 Since	 their	 discovery,	
IFNs	have	been	 immediately	 recognized	as	 important	 components	of	 innate	 immunity	
that	 activate	 significant	 host	 defense	 mechanisms	 with	 broad	 specificity	 (Isaacs	 and	
Lindenmann,	 I	 &	 II,	 1957;	 Lindenmann	 and	 Isaacs,	 1957).	 Nonetheless,	 it	 was	 only	 in	
1989	that	Charles	Janeway	articulated	a	unified	view	of	innate	immunity	to	incorporate	
past	 knowledge	 and	 add	 the	 concept	 of	 pathogen-associated	 molecular	 patterns	
(PAMPs).	Janeway	posited	that	PAMPs	were	repetitive	molecular	identifiers	that	bound	
to	 pattern	 recognition	 receptors	 (PRRs)	 on	 ‘innate’	 cells	 of	 the	 immune	 system	 and	
activated	them	to	participate	in	immune	induction	and	defense	(Janeway,	1989).		
After	 infecting	a	cell,	a	virus	must	start	 to	replicate	 its	genome.	The	viral	nucleic	acids	
produced	from	this	process	are	typically	recognized	by	different	PRRs	to	activate	several	
host	 cell	 antiviral	 responses,	 including	 the	 type	 I	 IFN	 response	 (Kumar	 et	 al.,	 2009).	
Infection	 by	 many	 viruses	 stimulates	 PRRs	 through	 the	 production	 of	 dsRNA.	 For	
example,	 toll-like	 receptor	 3	 is	 a	 sensor	 for	 double-stranded	 RNA	 (dsRNA)	 in	 the	
endosomal	 compartment,	whereas	 retinoic	acid-inducible	gene-I	 (RIG-I,	 also	known	as	
DDX58)	and	melanoma	differentiation-associated	gene-5	 (MDA5,	also	known	as	 IFIH1)	
are	activated	by	dsRNA	in	the	cytosol	(Saito,	2008;	Schroder,	2005).		
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While	 RIG-I	 detects	 5’-triphosphorylated	 dsRNA,	MDA5	 detects	 long	 dsRNA	 of	 >2000	
base	 pairs.	 MDA5	 detects	 and	 mediates	 response	 to	 a	 group	 of	 positive	 strand	 RNA	
viruses	 including	 encephalomyocarditis	 virus,	 murine	 norovirus,	 picornaviruses,	
polioviruses,	and	coronaviruses	 (Gitlin	et	al.,	2006;	Kato	et	al.,	2006;	McCartney	et	al.,	
2008;	Roth-Cross	et	al.,	2008).	 IFN	 response	 to	MHV	 infection	 is	dependent	on	MDA5	
and	not	on	RIG-I.		
	
MDA5	 is	 a	 cytosolic	 RIG-I-like	 helicase.	 Like	 RIG-I,	 MDA5	 contains	 a	 DExH-box	 (DECH	
variants)	helicase	domain	through	which	it	binds	dsRNA	and	catalyzes	hydrolysis	of	ATP.	
MDA5	 has	 a	 low	 affinity	 for	 its	 RNA	 substrate,	 and	may	 be	 assisted	 by	 Laboratory	 of	
Genetics	 and	 Physiology	 2	 (LGP2),	 another	 RIG-I	 like	 helicase,	 to	 interact	 with	 the	
adaptor	protein	mitochondrial	antiviral	signaling	protein	(MAVS)	(Rodriguez	et	al.,	2014;	
Hou	et	al.,	2011;	H.	Xu	et	al.,	2014b).	MAVS,	also	known	as	promoter	stimulator-1	(IPS-
1),	 links	 both	MDA5	 and	 RIG-I	 to	 downstream	 signaling	molecules	 (Jiang	 et	 al.,	 2011;	
Kowalinski	 et	 al.,	 2011;	 Luo	 et	 al.,	 2011;	 Zeng	 et	 al.,	 2010).	 Once	 activated,	 MAVS	
propagates	 the	signal	 to	 the	cytosolic	protein	kinase	 IκB	 (IKK)	and	 to	 the	 transcription	
factor	 nuclear	 factor	 kappa-light-chain-enhancer	 of	 activated	 B	 cells	 (NF-κB).	 IKK	
associates	 with	 TANK-binding	 kinase	 1	 (TBK1)	 to	 phosphorylate	 and	 activate	 the	
transcription	factor	interferon	regulatory	factor	3	(IRF3)	(Yoneyama	et	al.,	2004).	These	
transcription	factors	promote	transcription	of	many	 interferon-stimulated	genes	 (ISGs)	
and	IFN	subtypes.			
	
The	products	of	these	ISGs	exert	numerous	antiviral	effector	functions,	many	of	which	
are	still	not	fully	described.	Recent	efforts	have	been	aimed	at	identifying	which	ISGs	are	
antiviral	and	further	characterizing	their	mechanisms	of	action.	Type	I	(IFNα/β)	and	type	
III	(IL28A,	IL28B,	IL29)	IFNs	are	often	considered	the	antiviral	classes,	although	type	II	IFN	
(IFNγ)	 also	 has	 well-described	 antiviral	 properties	 (Borden,	 2007).	 Each	 of	 these	 IFNs	
induces	a	unique	and	partially	overlapping	set	of	ISGs	(Der,	1998).	In	addition,	some	ISGs	
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are	directly	induced	by	viral	infection	in	the	absence	of	IFN	production	(Sen,	2007).	This	
leads	to	ISG	induction	through	multiple	mechanisms	that	are	intersecting	and	often	self-
reinforcing.	Collectively,	ISGs	can	target	almost	any	step	in	a	virus	life	cycle.	Some	of	the	
most	 potent	 antiviral	 effectors	 reinforce	 the	 system	 by	 further	 inducing	 IFN	 or	 ISGs.	
Other	 genes	 enhance	 or	 facilitate	 viral	 replication,	 suggesting	 that	 some	 viruses	may	
have	 evolved	 to	 co-opt	 IFN	 effectors	 for	 a	 survival	 advantage.	 Independent	 to	 the	
activation	 of	 ISGs,	 dsRNA	 sensing	 by	 cells	 also	 stimulates	 direct	 induction	 of	 several	
genes,	via	 IRFs	or	NF-κB.	These	have	been	 termed	viral	 stress	 inducible	genes	 (Sarkar,	
2004)	and	different	dsRNA	sensors	are	involved	in	their	induction.	
	
Type	I	IFNs,	primarily	IFNα	and	IFNβ	(Kumar	et	al.,	2009),	are	produced	by	infected	cells	
and	act	in	an	autocrine	and	paracrine	manner	to	induce	antiviral	activities	in	both	virus-
infected	 cells	 and	 neighboring	 uninfected	 cells.	 Innate	 immune	 cells,	 such	 as	
macrophages	and	dendritic	cells	(DCs),	produce	type	I	 IFNs	after	sensing	pathogens.	 In	
particular,	plasmacytoid	DCs	(pDCs)	produce	large	quantities	of	IFNα.	A	single	IFNβ	gene	
encodes	IFNβ,	whereas	14	distinct	genes	encode	various	IFNα	isoforms	in	mice	(Pestka,	
Krause,	 2004;	 Hertzog,	 2013;	 Paludan,	2013;	 Goubau.	 2013;	 Iwasaki,	 2012).	 Secreted	
IFNα	and	IFNβ	bind	a	heterodimeric	transmembrane	receptor	termed	the	IFNα	receptor	
(IFNAR1),	which	is	composed	of	IFNAR1	and	IFNAR2	subunits.	In	the	canonical	type	I	IFN-
induced	signaling	pathway	described	over	25	years	ago,	IFNAR	engagement	was	shown	
to	activate	 the	 receptor-associated	protein	 tyrosine	 kinases	 Janus	 kinase	1	 (JAK1)	 and	
tyrosine	 kinase	 2	 (TYK2),	 which	 phosphorylate	 the	 latent	 cytoplasmic	 transcription	
factors	STAT1	and	STAT2	(Levy,	2002;	Stark,	2012).	Tyrosine-phosphorylated	STAT1	and	
STAT2	 dimerize	 and	 translocate	 to	 the	 nucleus,	 where	 they	 assemble	 with	 IFN-
regulatory	 factor	 9	 (IRF9)	 to	 form	 a	 trimolecular	 complex	 called	 IFN-stimulated	 gene	
factor	 3	 (ISGF3).	 ISGF3	binds	 to	 its	 cognate	DNA	 sequences,	which	 are	 known	as	 IFN-
stimulated	 response	 elements	 (ISREs),	 thereby	 directly	 activating	 the	 transcription	 of	
ISGs.	By	contrast,	most	other	cytokines	activate	STAT	homodimers	that	bind	to	a	distinct	
gamma-activated	sequence	(GAS).	Thus,	canonical	type	I	IFN	signaling	induces	a	distinct	
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subset	of	several	hundred	ISRE-driven	ISGs,	many	of	which	establish	a	cellular	antiviral	
state.	 ISG-encoded	 proteins	 restrict	 pathogens	 by	 several	 mechanisms,	 including	 the	
inhibition	of	viral	transcription,	translation,	and	replication	and	the	degradation	of	viral	
nucleic	acids	(Stark,	2012;	MacMicking,	2012;	Schoggins,	2011;	Rusinova,	2012).	
	
The	IFN	response	is	a	broad	and	early	innate	host	defense	against	viral	infection	that	is	
crucial	 to	 survival	 of	 mice	 as	 evidenced	 by	 the	 extreme	 susceptibility	 of	 IFNAR1	
knockout	mice	 to	 infection	with	many	 viruses,	 including	MHV.	 This	 genotype	of	mice,	
once	 infected	 by	 MHV-A59	 are	 observed	 to	 have	 enhanced	 replication	 in	 normally	
infected	organs	 (brain,	 liver,	and	spleen)	and	 increased	spread	to	other	organs	 (heart,	
lung,	 kidney,	 stomach,	 and	 spleen)	 not	 normally	 infected	 in	 WT	 B6	 mice.	 IFNAR1	
knockout	mice	succumb	to	MHV	infection	in	less	than	two	days	(Cervantes-Barragan	et	
al.,	 2007;	 Ireland	 et	 al.,	 2008;	 Roth-Cross	 et	 al.,	 2008).	 Cellular	 responses	 to	 IFNAR	
ligation	are	cell	type-	and	context-dependent	and	vary	during	the	course	of	an	immune	
response	 (van	 Boxel-Dezaire,	 2006;	 Trinchieri,	 2010).	 This	 variation	 results	 from	 cell	
lineage	 and	 developmental	 differences	 that	 alter	 how	 cells	 interpret	 IFNAR-induced	
signals,	and	 from	the	modulation	of	 IFNAR	signaling	and	 ISG	expression	by	concurrent	
signals	induced	by	pathogens,	PRRs,	and	immune	and	environmental	factors.		
Furthermore,	cytosolic	receptors	for	viral	RNA	have	long	been	recognized.	In	the	1970s,	
biochemical	 evidence	 identified	 the	 two	 earliest-discovered	 and	 most	 extensively	
studied	mediators	of	 the	antiviral	 activity	of	 IFNs,	RNase	L	and	protein	kinase	R	 (PKR)	
(Sadler	 et	 al.,	 2008).	 Both	 of	 these	 receptors	 bind	 to	 dsRNA	 but	 have	 different	
mechanisms	of	action.	Activation	of	PKR	enables	the	phosphorylation	of	 its	substrates,	
which	 include	 the	 α	 subunit	 of	 the	 pivotal	 translation	 initiation	 factor	 eIF2.	
Phosphorylation	 causes	 eIF2	 to	 bind	 irreversibly	 to	 the	 nucleotide	 exchange	 factor	
eIF2B,	 thereby	 preventing	 recycling	 of	 eIF2	 and	 shutting	 down	 host	 cell	 protein	
synthesis.	 MHV	 does	 not	 lead	 to	 eIF2	 phosphorylation	 suggesting	 that	 this	 virus	 has	
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mechanisms	that	bypass	PKR	(Koetzner,	2010).	Activation	of	RNase	L	is	discussed	in	the	
following	section.		
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I.5	 OAS-RIBONUCLEASE	LATENT		
The	 other	 potent	 antiviral	 IFN-induced	 activity	 is	 the	 2’,5’-oligoadenylate	 synthetase-
endoribonuclease	latent	(OAS-RNase	L)	pathway	(Sadler	and	Williams,	2008).	The	OAS-
RNase	 L	 axis	 was	 one	 of	 the	 first	 antiviral	 pathways	 discovered	 in	 the	 mid-1970s	
(Hovanessian,	 1977;	 Clemens	 and	Williams	1978;	 Kerr	 and	 Brown	1978;	 Ratner,	1978;	
Slattery,	 1979).	 RNase	 L	 is	 a	 highly	 regulated,	 latent	 endoribonuclease	 first	 cloned	 in	
1993	when	it	was	referred	to	as	the	2-5A-dependent	RNase	(Zhou	et	al.,	1993).	RNase	L	
mRNA	and	protein	 are	 constitutively	 expressed	 in	most,	 if	 not	 all,	mammalian	 tissues	
through	 transcriptional	 and	post-transcriptional	mechanisms	 (Bisbal,	 et	 al.,	 1995;	 Li	 et	
al.,	 2000;	 Zhou	 et	 al.,	 2005).	 RNase	 L	 activity	 is	 controlled	 primarily	 at	 the	 post-
transcriptional	 level	 by	 the	 availability	 of	 2-5A,	 whose	 production	 is	 dependent	 on	
dsRNA	presence	in	a	cell	that	is	sensed	by	OAS	proteins.		
OAS	 proteins	 are	 pathogen	 recognition	 receptors	 (PRR)	 for	 the	 viral	 pathogen-
associated	molecular	pattern	–	dsRNA.	During	the	lifecycle	of	MHV,	dsRNA	is	produced	
in	the	cytosol	of	cells,	which	is	sensed	by	OAS	proteins.	Once	stimulated	by	dsRNA,	OAS	
uses	 ATP	 to	 synthesize	 2-5A	 molecules	 of	 the	 formula	 [px5ʹA(2ʹp5ʹA)n;	x = 1–3;	n > 2],	
yielding	a	5ʹ-triphosphorylated	triadenylate	with	2’,5’-phosphodiesterase	linkages.	Mice	
express	several	OAS	proteins	that	produce	2-5A,	including	OAS1A/G,	OAS2,	OAS3	as	well	
as	OASL2	(Kakuta,	Shibata,	&	Iwakura,	2002;	Kalinichenko	et	al.,	2004;	Mashimo	et	al.,	
2003).	The	concentration	of	2-5A	is	believed	to	be	the	primary	factor	controlling	RNase	L	
activation.	 At	 subnanomolar	 levels,	 2-5A	 binds	 to	 the	 ubiquitous	 cellular	 RNase	 L,	
causing	 inactive	 RNase	 L	 monomers	 to	 form	 activated	 dimers	 (Dong	 and	 Silverman,	
1995).	 Active	 RNase	 L	 cleaves	 single-stranded	 RNA	 (ssRNA)	 in	 uracil-rich	 sequences,	
typically	 after	 double	 uracil	 or	 uracil-adenosine	 dinucleotides	 (Floyd-Smith,	 1981;	
Wreschner,	1981b).		
	
The	RNase	L	antiviral	mechanism	varies,	depending	on	the	types	of	RNA	molecules	that	
are	cleaved.	If	the	RNA	substrate	for	RNase	L	is	viral	genomic	single-stranded	RNA,	even	
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a	 single	 cleavage	 event	 per	 viral	 genome	might	 prevent	 replication.	 Cleavage	 of	 viral	
mRNA	 is	 a	 mechanism	 that	 could	 potentially	 apply	 to	 RNA	 and	 DNA	 viruses	 with	
different	replication	strategies.	Indeed,	the	antiviral	activity	of	the	OAS-RNase	L	pathway	
has	been	demonstrated	during	infections	of	mice	with	numerous	RNA	and	DNA	viruses	
(Flodström-Tullberg	et	al.,	2005;	Li	et	al.,	1998;	Samuel	et	al.,	2006;	Scherbik	et	al.,	2006;	
Washenberger	et	al.,	2007;	Xiang	et	al.,	2002;	Zhou	et	al.,	1997).	
In	 addition,	 degradation	 of	 cellular	 RNA,	 including	 rRNA	 in	 intact	 ribosomes,	 could	
damage	host	cell	machinery	required	for	protein	synthesis	 (Li,	2004;	Silverman,	1983).	
Also,	 RNase	 L	 restricts	 viral	 infections	 by	 causing	 apoptosis	 through	 an	 unknown	
mechanism	involving	Jun	N-terminal	kinase	(JNK)	(Zhou,	1997;	Li,	2004;	Castelli,	1997).	
Furthermore,	 RNase	 L	 activation	 results	 in	 autophagy	 in	 a	 pathway	 involving	 JNK	 and	
protein	kinase	R	(PKR)	that	can	either	enhance	or	decrease	viral	replication	(Chakrabarti,	
2012;	 Siddiqui,	 2012).	 Finally,	 effects	 of	 the	 OAS-RNase	 L	 pathway	 extend	 beyond	
initially	 infected	 cells	 to	 support	 a	 prolonged	 antiviral	 state	 in	 some	 cell	 types	 and	
organisms	 through	 further	 induction	 and	 section	of	 IFN	by	 the	 small	 RNAs	 created	 as	
products	of	RNase	L	digestion	(Malathi,	2007;	Silverman,	2007).	
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1.6	 ANTAGONISM	OF	THE	RNASE	L	PATHWAY	
In	 response	 to	 cellular	 defenses	 such	 as	 the	 host	 type	 I	 IFN	 response,	 viruses	 have	
evolved	countermeasures.	Viruses	from	diverse	families	express	proteins	that	block	IFN	
induction	and	signaling	pathways,	such	as	the	PKR	and	OAS-RNase	L	pathways.	This	was	
reinforced	 by	 studies	 of	 mice	 deficient	 in	 these	 pathways	 that	 revealed	 enhanced	
sensitivity	 to	 infection	 by	 a	 range	 of	 viruses.	 However,	 although	 these	 antiviral	
mechanisms	were	clearly	important	at	both	a	cellular	and	an	organismal	level,	they	did	
not	account	for	the	development	of	a	virus-specific	immune	response.		
	
Indeed,	 while	 there	 were	 no	 significant	 differences	 in	 viral	 titers	 or	 pathology	 in	 the	
livers	 of	 A59-infected	 B6	 and	 Rnasel−/−	 mice	 during	 early	 infection,	 later	 timepoints	
revealed	that	the	livers	of	infected	Rnasel−/−	mice	have	significant	titers	of	virus,	antigen	
expression,	and	pathology,	implying	that	Rnasel−/−	mice	are	defective	in	viral	clearance.	
One	possible	reason	for	the	delay	in	clearance	is	that	Rnasel−/−	mice	have	lower	levels	of	
apoptosis	 and	 in	 addition	 are	 relatively	 resistant	 to	 apoptosis,	 resulting	 in	 increased	
numbers	of	cells	in	the	thymus	and	spleen	(Zhou	et	al.,	1997).	However,	Rnasel−/−	mice	
are	eventually	able	to	clear	virus	(Zhao	et	al.,	2012).		
	
The	 aforementioned	 studies	 underscore	 the	 importance	 of	 RNase	 L	 and	 its	 activities	
during	 MHV	 infection.	 Indeed,	 many	 viruses	 antagonize	 RNase	 L	 and	 its	 effects.	 For	
example,	encephalomyocarditis	virus	(EMCV)	(Zhou,	1993),	herpes	simplex	virus-1	(HSV-
1)	 (Austin,	 2005;	 Zheng,	 2001),	 vaccinia	 virus	 (VV)	 (Diaz-Guerra,	 1997),	 coxsackie	 B4	
virus	(Flodstrom-Tullberg,	2005),	West	Nile	virus	(Samuel,	2006),	Theiler’s	virus	(TMEV)	
(Sorgeloos,	2013),	and	Coronaviruses	(Cruz,	2011;	Zhao,	2012)	inhibit	antiviral	activity	of	
the	OAS-RNase	 L	pathway	by	expressing	antagonizing	proteins	 that	 are	 in	 some	cases	
vital	 for	 viral	 replication	 and	 pathogenesis	 (Randall	 &	 Goodbourn,	 2008;	 Silverman,	
2007;	Zhou	et	al.,	1997)).	One	of	the	most	common	and	well-characterized	mechanisms	
of	IFN	antagonism	is	the	binding	and	sequestering	of	dsRNA	by	proteins	such	as	VV	pE3L	
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(Chang	et	al.,	1992;	Xiang	et	al.,	2002),	influenza	virus	NS1	(Lu	et	al.,	1995;	Min	and	Krug,	
2006),	 reovirus	 σ3,	 and	 HSV-1	 pUS11	 (Schneider,	 2003).	 Binding	 to	 these	 proteins	
appears	 to	 neutralize	 the	 ability	 of	 dsRNA	 to	 activate	 cellular	 antiviral	 responses,	
including	activation	of	RNase	L.		
	
Another	 strategy	 of	 OAS-RNase	 L	 pathway	 antagonism	 is	 direct	 inhibition	 of	 RNase	 L	
activation.	 For	 example,	 human	 immunodeficiency	 virus	 (Martinand	 et	 al.,	 1999)	 and	
EMCV	 (Martinand	 et	 al.,	 1998)	 induce	 expression	 of	 an	 RNase	 L	 inhibitor	 protein,	 RLI	
(a.k.a.	 ABCE1).	 Group	 C	 enterovirus	 has	 a	 conserved	 RNA	 structure	 that	 inhibits	 the	
activity	 of	 RNase	 L	 (Townsend	 et	 al.,	 2008).	 HSV-1	 (Cayley	 et	 al.,	 1984)	 and	 Simian	
vacuolating	 virus	 40	 induces	 synthesis	 of	 2-5A	 derivatives	 that	 antagonize	 or	 fail	 to	
activate	RNase	L.	The	L*	of	TMEV	directly	inhibits	RNase	L	(Michiels,	2013).		
	
Among	 these	 direct	 forms	 of	 RNase	 L	 antagonism,	 MHV	 has	 evolved	 a	 unique	
mechanism	 mediated	 by	 nonstructural	 protein	 2	 (ns2).	 The	 ns2	 protein	 has	 2ʹ,5ʹ-
phosphodiesterase	 (PDE)	 activity	 that	 specifically	 cleaves	 2’,5’	 phosphodiester	 bonds	
and	 converts	 2-5A	 into	 ATP	 and	 AMP.	 Cleavage	 of	 2-5A	 by	 ns2	 profoundly	 limits	 the	
extent	 of	 RNase	 L	 activation	 thereby	 enhancing	 viral	 growth	 and	 viral	 pathogenesis	
(Zhao,	 2012).	 Furthermore,	 ns2	 is	 dispensable	 for	 virus	 replication	 in	 transformed	 cell	
lines	but	serves	as	an	IFN	antagonist	and	is	required	for	the	induction	of	hepatitis	in	vivo	
(Zhao,	 2012).	 As	 a	 member	 of	 group	 II	 (eukaryotic	 LigT)	 2H-phosphoesterase	
superfamily,	ns2	contains	two	HxT/S	(H,	histidine;	T,	threonine;	S,	serine;	x,	any	amino	
acid)	 catalytic	motifs.	 This	 group	 contains	 cellular	proteins	 such	as	A-kinase-anchoring	
protein-7	(AKAP7)	and	viral	proteins,	including	VP3	of	group	A	rotavirus,	polypeptide	1a	
of	 torovirus	 (Mazumder,	2002),	and	NS4b	of	MERS-CoV	 (unpublished).	 Introduction	of	
amino	acid	substitutions	into	the	predicted	catalytic	histidine	residues	(Roth-Cross	et	al.,	
2009)	 attenuates	MHV-A59	 replication	 in	 the	 liver	 and	 reduces	hepatitis	 to	 a	minimal	
level	 without	 affecting	 viral	 replication	 in	 the	 brain	 or	 without	 reducing	 encephalitis	
(Roth-Cross	 et	 al.,	 2009).	 This	mutant	 strain	 is	 known	 as	 ns2H126R.	 This	mutant	 strain	
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expresses	 an	 enzymatically	 inactive	 ns2	 with	 a	 histidine-to-arginine	 amino	 acid	
substitution	at	position	126.	 In	 conjunction	with	 the	WT	MHV-A59	strain,	 the	ns2H126R	
mutant	 strain	 is	 used	 extensively	 throughout	 this	 thesis	 and	 is	 used	 to	 elucidate	 the	
organ-specific	 and	 cell	 type-specific	 nature	 of	 RNase	 L	 antagonism	 during	 MHV	
infection.		
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I.7	 AIMS	OF	DISSERTATION		
MHV	differs	from	many	other	viruses	in	that	it	stimulates	type	I	IFN	production	in	only	
limited	cell	types,	primarily	 in	macrophages	(Roth-Cross	et	al.,	2008)	and	plasmacytoid	
dendritic	 cells	 (Cervantes-Barragan	 et	 al.,	 2007).	 Furthermore,	MHV	 displays	 cell-type	
specific	 sensitivity	 to	 the	 antiviral	 effects	 of	 IFN	 treatment,	 with	macrophage	 lineage	
cells	being	most	successful	in	restricting	MHV	replication	(Rose	and	Weiss,	2009;	Zhao	et	
al.,	 2011).	 Additionally,	 in	 contrast	 to	 its	 infection	 of	 the	 liver,	 ns2H126R	 can	 replicate	
efficiently,	to	a	similar	extent	as	MHV-A59	in	the	CNS	of	B6	mice,	as	well	as	in	cell	lines	
and	some	primary	cells	 (Zhao	et	al.	 ,	2011).	These	observations	suggest	 that	MHV	has	
evolved	mechanisms	 to	antagonize	 the	 IFN	 response	 in	a	 cell	 type-specific	and	organ-
specific	 fashion,	which	may	 influence	 pathogenesis	 in	 vivo.	 It	 is	 unclear	why	 RNase	 L	
activation	is	organ-	and	cell-type	specific	and	most	robust	in	myeloid-derived	cells.	This	
thesis	 aims	 to	 investigate	 the	 mechanisms	 underlying	 activation	 of	 the	 OAS-RNase	 L	
pathway	and	its	antagonism	by	a	virus	induced	phosphodiesterase.		
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II	
CHAPTER	TWO	
CELL-TYPE	SPECIFIC	ACTIVATION	OF	THE	OLIGOADENYLATE	SYNTHETASE-	
RNASE	L	PATHWAY	BY	A	MURINE	CORONAVIRUS	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
This	 chapter	 appeared	 as	 a	 published	 peer-reviewed	 article	 titled	 “Cell-type	 specific	
activation	of	the	oligoadenylate	synthetase-RNase	L	pathway	by	a	murine	coronavirus”	
by	 L.	 Zhao,	 L.	 Dillon	 Birdwell§,	 A.	 Wu,	 R.	 Elliott,	 K.	 M.	 Rose,	 J.	 M.	 Phillips,	 Y.	 Li,	 J.	
Grinspan,	R.	H.	Silverman,	and	S.	R.	Weiss.	Journal	of	Virology,	2013.	
	
§LDB	and	LZ	contributed	equally	to	this	work.	
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II.1	 ABSTRACT	
Previous	studies	have	demonstrated	that	the	murine	coronavirus	mouse	hepatitis	virus	
(MHV)	 nonstructural	 protein	 2	 (ns2)	 is	 a	 2’,	 5’-phosphodiesterase	 that	 inhibits	 active-
tion	 of	 the	 interferon-induced	 oligoadenylate	 synthetase	 (OAS)-RNase	 L	 pathway.	
Enzymatically	 active	 ns2	 is	 required	 for	 efficient	MHV	 replication	 in	macrophages,	 as	
well	as	for	the	induction	of	hepatitis	in	C57BL/6	mice.	In	contrast,	following	intranasal	or	
intracranial	inoculation,	efficient	replication	of	MHV	in	the	brain	is	not	dependent	on	an	
enzymatically	 active	 ns2.	 The	 replication	 of	 wild-type	 MHV	 strain	 A59	 (A59)	 and	 a	
mutant	 with	 an	 inactive	 phosphodiesterase	 (ns2H126R)	 was	 assessed	 in	 primary	
hepatocytes	and	primary	central	nervous	system	(CNS)	cell	types—neurons,	astrocytes,	
and	oligodendrocytes.	A59	and	ns2H126R	 replicated	with	similar	kinetics	 in	all	cell	 types	
tested,	 except	 macrophages	 and	 microglia.	 RNase	 L	 activity,	 as	 assessed	 by	 rRNA	
cleavage,	 was	 induced	 by	 ns2H126R,	 but	 not	 by	 A59,	 and	 only	 in	 macrophages	 and	
microglia.	Activation	of	RNase	L	correlated	with	 the	 induction	of	 type	 I	 interferon	and	
the	consequent	high	 levels	of	Oas	mRNA	 induced	 in	 these	cell	 types.	Pretreatment	of	
nonmyeloid	 cells	 with	 interferon	 restricted	 A59	 and	 ns2H126R	 to	 the	 same	 extent	 and	
failed	 to	 activate	 RNase	 L	 following	 infection,	 despite	 induction	 of	 Oas	 expression.	
However,	 rRNA	 degradation	 was	 induced	 by	 treatment	 of	 astrocytes	 or	
oligodendrocytes	with	 poly(I:C).	 Thus,	 RNase	 L	 activation	 during	MHV	 infection	 is	 cell	
type	specific	and	correlates	with	relatively	high	levels	of	expression	of	Oas	genes,	which	
are	necessary	but	not	sufficient	for	induction	of	an	effective	RNase	L	antiviral	response.	
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II.2	 INTRODUCTION	
The	murine	coronavirus,	mouse	hepatitis	virus	(MHV),	 is	an	enveloped,	positive-strand	
RNA	virus	of	the	coronavirus	 family,	within	the	nidovirus	order.	MHV	is	a	collection	of	
strains	with	tropisms	for	different	organs,	including	the	liver	and	central	nervous	system	
(CNS),	and	thus	provides	models	for	the	study	of	acute	encephalitis	and	hepatitis	as	well	
as	chronic	demyelinating	disease.	The	MHV-A59	strain	(A59)	used	in	this	study	induces	
mild	 encephalitis	 and	moderate	hepatitis.	 Studies	of	 the	pathogenesis	 of	MHV	 strains	
and	 recombinant	 chimeric	 MHVs	 have	 shown	 that	 post	 entry	 virus–host	 interactions	
have	significant	impact	on	organ	tropism	and	virulence	in	MHV	infected	mice	(Navas	&	
Weiss,	2003;	Zhao,	Rose,	Elliott,	Van	Rooijen,	&	Weiss,	2011).		
	
The	 type	 I	 IFN	 response	 is	 an	 early	 innate	 response	 that	 is	 crucial	 to	 survival	 of	mice	
following	infection	with	many	viruses,	 including	MHV	(Cervantes-Barragan	et	al.,	2007;	
Ireland,	Stohlman,	Hinton,	Atkinson,	&	Bergmann,	2008;	Roth-Cross,	Bender,	&	Weiss,	
2008).	During	infection,	viral	dsRNA	is	recognized	by	pattern	recognition	receptors,	such	
as	MDA5	in	the	case	of	MHV	in	most	cell	types	(Cervantes-Barragan	et	al.,	2007;	Ireland	
et	al.,	2008;	Roth-Cross	et	al.,	2008);	this	leads	to	the	synthesis	of	type	I	IFN	(Figure	2.1).	
IFNα,	 β	 induces	 expression	 of	 interferon-stimulated	 genes	 (ISGs)	 encoding	 pattern	
recognition	 receptors,	 transcription	 factors,	 and	 antiviral	 effectors,	 including	multiple	
oligoadenylate	 synthetase	 (OAS)	 proteins.	 Viral	 dsRNA	 directly	 binds	 to	 and	 activates	
OAS	 to	 synthesize	 2’,	 5’-linked	 oligoadenylates	 (2-5A),	 which	 induce	 RNase	 L	
dimerization	 and	 activity	 (Dong	&	 Silverman,	 1995;	Malathi,	Dong,	Gale,	&	 Silverman,	
2007;	Silverman,	2007).	RNase	L	is	a	particularly	potent	antiviral	effector	in	that	it	both	
directly	cleaves	viral	and	host	RNA,	thereby	reducing	the	amount	of	viral	RNA	available	
for	replication	and	packaging	of	genome	into	progeny	virus,	and	inhibits	host	and	viral	
protein	 synthesis.	 In	 addition,	 RNase	 L-mediated	 cleavage	 generates	 additional	 small	
RNAs	 that	 can	 be	 recognized	 by	 cytoplasmic	 pattern	 recognition	 receptors,	 further	
amplifying	 IFN	synthesis	 (A.	 Zhou	et	al.,	 1997).	 Importantly	and	unlike	most	other	 IFN	
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induced	activities,	activation	of	 the	OAS-RNase	L	pathway	requires	both	viral	 infection	
(production	of	ds	RNA)	and	type	I	IFN	exposure	(upregulation	of	OAS)	in	the	same	cell	in	
order	to	produce	sufficient	2-5A	to	activate	RNase	L.		
	
Many	 viruses,	 including	 MHV,	 have	 evolved	 mechanisms	 to	 avoid	 and/or	 antagonize	
host	 type	 I	 IFN	 responses	 (Randall	 &	 Goodbourn,	 2008),	 including	 the	 OAS-RNase	 L	
pathway	(Silverman,	2007;	A.	Zhou	et	al.,	1997).	We	have	shown	previously	that	the	A59	
accessory	protein	ns2	is	a	type	I	IFN	antagonist.	ns2	has	2’,	5’-phosphodiesterase	activity	
that	 cleaves	 2-5A,	 thereby	 antagonizing	 the	 activation	 of	 the	 OAS-RNase	 L	 pathway	
(Zhao	 et	 al.,	 2012).	 An	 ns2	 mutant	 of	 A59	 (ns2H126R),	 expressing	 an	 inactive	
phosphodiesterase,	was	unable	to	replicate	efficiently	in	macrophages	derived	from	B6	
mice,	 indicating	that	an	active	ns2	 is	required	for	robust	replication	of	A59	 in	that	cell	
type.	However,	ns2H126R	was	able	 to	 replicate	efficiently	 in	macrophages	derived	 from	
mice	deficient	in	either	type	I	interferon	receptor	expression	(Ifnar1-/-)	mice	or	RNase	L	
expression	 (Rnasel-/-)	 (Zhao	et	al.,	2012;	Zhao	et	al.,	2011).	These	and	other	published	
data	 (Zhao	et	al.,	2012;	Zhao	et	al.,	2011)	 led	us	to	conclude	that	ns2	antagonizes	 IFN	
signaling,	by	downregulating	RNase	L	activation.	Furthermore,	in	vivo,	ns2	acts	an	organ-
specific	 virulence	 factor	 that	 is	 required	 for	 efficient	 hepatic	 virus	 replication	 and	
pathology	in	B6	mice	(Roth-Cross	et	al.,	2009;	Zhao	et	al.,	2011).	Macrophage	depletion	
promoted	the	replication	of	ns2H126R	in	the	liver	to	a	level	close	to	that	of	wild	type	virus.	
This	observation	emphasizes	the	crucial	role	of	the	type	I	IFN	response	in	macrophages	
in	protecting	the	host	from	MHV	induced	hepatitis	(Zhao	et	al.,	2011).	
In	 contrast	 to	 its	 infection	 of	 the	 liver,	 ns2H126R	 can	 replicate	 efficiently,	 to	 a	 similar	
extent	as	A59	in	the	central	nervous	system	(CNS)	of	B6	mice,	as	well	as	in	cell	lines	and	
some	 primary	 cells	 (Zhao	 et	 al.,	 2011).	 Here,	 we	 have	 further	 investigated	 the	
mechanisms	underlying	the	organ	and	cell	type	specific	requirements	for	ns2-mediated	
IFN	antagonism	in	the	efficient	replication	of	MHV.	We	have	compared	the	Oas	mRNA	
expression	levels	as	well	as	the	replication	of	A59	and	ns2H126R	between	the	liver	and	the	
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brain	 and	 among	macrophages	 and	 brain	 and	 liver	 parenchymal	 cell	 types.	 Our	 data	
suggest	 that	 activation	 of	 the	OAS-RNase	 L	 pathway	 depends	 in	 part	 on	 the	 levels	 of	
expression	 of	 Oas	 genes.	 Furthermore,	 activation	 of	 this	 pathway	 is	 most	 robust	 in	
myeloid	 lineage	 cells	 and	 successful	 replication	 in	 myeloid	 cells	 is	 a	 pre-requisite	 for	
replication	in	the	liver	but	not	in	the	CNS.	
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II.3	 OBSERVATIONS	
II.3.i	 MHV	 replication	 depends	 on	 ns2-phosphodiesterase	 activity	 in	 an	 organ	
specific	manner		
MHV	strain	A59	 infects	predominantly	 the	central	nervous	system	(CNS)	and	the	 liver,	
resulting	 in	 mild	 encephalitis	 and	 moderate	 hepatitis	 (Weiss	 &	 Leibowitz,	 2011).	 We	
have	shown	previously	that	amino	acid	substitution	at	either	of	the	predicted	catalytic	
phosphodiesterase	residue,	H46A	or	H126R,	of	the	A59	ns2	protein	confers	attenuation	
of	 viral	 replication	and	pathogenicity	 in	 the	 liver	but	not	 in	 the	brain	of	C57BL/6	 (B6)	
mice	 (Zhao	 et	 al.,	 2011).	 We	 have	 now	 compared	 replication	 of	 wild	 type	 A59	 and	
mutant	ns2H126R	in	the	brain	and	liver	between	Rnasel-/-	mice	and	B6	mice	by	quantifying	
the	infectious	viral	titers	in	each	organ	5	days	following	intracranial	inoculation	with	200	
PFU/mouse	of	each	virus,	which	corresponds	to	the	peak	of	viral	infection	(Figure	2.2A).	
The	 infectious	 virus	 titers	 did	 not	 differ	 significantly	 between	 the	 brains	 of	 B6	 and	
Rnasel-/-	mice	infected	with	either	A59	or	mutant	ns2H126R.	In	contrast,	titers	of	ns2H126R	
were	more	than	100-fold	lower	than	those	of	A59	(p	=	0.0052)	in	the	livers	of	infected	
B6	mice	at	5	dpi,	consistent	with	previously	observed	results	of	intrahepatic	inoculation	
(Zhao	 et	 al.,	 2012;	 Zhao	 et	 al.,	 2011).	 The	 titers	 of	 ns2H126R	 and	 A59	 in	 the	 livers	 of	
Rnasel-/-	mice	were	not	 significantly	different,	 further	 illustrating	 the	 role	of	ns2	as	an	
antagonist	of	RNase	L	activation.		
	
We	reasoned	that	host	defenses	might	be	higher	when	virus	enters	the	brain	by	a	more	
natural	 route	 of	 infection	 (Fensterl	 et	 al.,	 2012).	 Thus,	 to	 further	 investigate	 the	
requirement	for	ns2	expression	for	MHV	replication	in	the	CNS,	B6	mice	were	infected	
intranasally	with	2x105	PFU	A59	or	ns2H126R	and	the	virus	titers	 in	the	brain	and	liver	5	
dpi	were	quantified	(Figure	2.2B).	Again,	the	titers	in	the	brain	did	not	differ	significantly	
between	A59	and	ns2H126R	infected	mice	5	dpi,	while	the	titers	of	A59	in	the	liver	were	
significantly	greater	than	that	of	ns2H126R	 (p	=	0.0006).	The	A59	titers	 in	the	 liver	were	
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approximately	1000	fold	higher	than	the	minimal	titers	of	ns2H126R.	Thus,	dispensability	
of	ns2	activity	for	replication	in	the	brain	was	independent	of	the	route	of	inoculation.		
	
RNase	 L	 activation	 depends	 on	 the	 level	 of	 2-5A,	 which	 is	 produced	 by	 several	 OAS	
proteins	upon	activation	by	viral	dsRNA.	We	used	quantitative	reverse	transcriptase-PCR	
(qRT-PCR)	to	compare	the	basal	 levels	of	expression	of	three	active	Oas	genes,	Oas1a,	
Oas2	and	Oas3,	between	the	brain	and	liver	of	uninfected	B6	mice	(Zhao	et	al.,	2012)	(2.	
2C).	We	found	that	the	basal	mRNA	expression	levels	of	Oas1a,	Oas2,	and	Oas3	in	naïve	
mice	were	significantly	higher	 in	the	 liver	than	 in	the	brain,	as	we	reported	previously	
for	other	 IFN-induced	genes	 (Zhao	et	al.,	2011).	This	 suggests	 that	basal	 levels	of	OAS	
might	 influence	 the	host’s	ability	 to	activate	RNase	L	and	 restrict	MHV	 infection	 in	an	
organ-specific	manner.	 The	 levels	 of	 RNase	 L	mRNA	 expression	were	 similar	 between	
the	brain	and	 liver	 (Figure	2.2C)	and	do	not	 likely	 contribute	 to	 the	differences	 in	 the	
effects	of	viral	phosphodiesterase	activity.	
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II.3.ii	 Efficient	replication	of	MHV	in	hepatocytes	does	not	require	antagonism	of	the	
OAS-RNase	L	pathway		
We	previously	observed	that	macrophages,	unlike	transformed	fibroblast	cell	 lines	and	
other	primary	cell	types	tested,	restrict	replication	of	more	effectively	than	that	of	A59	
and	that	in	vivo	depletion	of	macrophages	allowed	to	cause	hepatitis	in	B6	mice	(Zhao	et	
al.,	2011).	Based	on	these	data,	we	hypothesized	that	liver	parenchymal	cells	were	less	
well	prepared	than	macrophages	to	restrict	MHV.	To	test	this	hypothesis,	we	compared	
replication	of	A59	and	ns2H126R	in	hepatocytes,	the	most	abundant	cell	type	in	the	liver	
parenchyma,	and	in	macrophages.	Primary	hepatocyte	cultures	(Figure	2.3A)	and	bone	
marrow	derived	macrophages	(BMM)	(Figure	2.3B)	were	infected	with	A59	or	ns2H126R,	
and	 the	 replication	 kinetics	 were	 compared	 between	 the	 isolates	 for	 each	 cell	 type.	
While	 BMM	 severely	 restricted	 ns2H126R	 replication	 relative	 to	 A59,	 both	 viruses	
replicated	 with	 similar	 kinetics	 and	 to	 similar	 final	 titers	 in	 primary	 hepatocytes.	 In	
addition,	 both	 viruses	 produced	 syncytia	 in	 hepatocytes,	 as	 observed	 by	 staining	 the	
cultures	with	an	antibody	directed	against	the	MHV	nucleocapsid	protein	(Figure	2.3C).	
We	next	compared	the	effects	of	IFN	pretreatment	on	replication	of	A59	and	ns2H126R	in	
hepatocytes.	Cultures	were	treated	with	100	U/ml	of	IFNα	for	24	hours	before	infection.	
Virus	was	quantified	from	the	supernatant	at	several	times	post	infection.	IFN	treatment	
of	hepatocytes	decreased	viral	titers	100-fold	relative	to	control	wells	by	16	hpi	(Figure	
2.3D).	 However,	 ns2H126R	 and	 A59	 replicated	 to	 similar	 levels	 in	 IFN-treated	 cells,	
indicating	that	IFN	treatment	of	hepatocytes	induces	a	robust	anti-MHV	response	that	is	
not	 dependent	 on	 RNase	 L	 activation.	 Consistent	 with	 this	 observation,	 RNase	 L-
mediated	 degradation	 of	 ribosomal	 RNA	 (rRNA)	 was	 not	 detected	 in	 hepatocytes	
infected	 with	 A59	 or	 ns2H126R,	 as	 assessed	 by	 Bioanalyzer	 analysis	 (described	 in	
Experimental	Framework	and	Notation)	(Figure	2.3E).		
	
We	reasoned	that	an	adequate	level	of	expression	of	OAS,	the	producer	of	2-5A,	would	
be	a	requirement	for	the	activation	of	RNase	L	and	furthermore,	that	the	 level	of	OAS	
could	 vary	 among	 cell	 types.	 To	 further	 investigate	 the	 mechanisms	 underlying	 the	
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difference	in	RNase	L	activation	between	macrophages	and	hepatocytes,	we	compared	
the	basal	levels	of	expression	of	several	genes	encoding	active	OAS	proteins	and	found	
that	 Oas	 mRNAs	 levels	 were	 100	 to	 1000-fold	 higher	 in	 macrophages	 than	 in	
hepatocytes	(Figure	2.4A).	Even	following	MHV	infection,	at	16	hpi,	Oas1a	mRNA	levels	
remained	 comparatively	 low	 in	 hepatocytes	 relative	 to	macrophages	 (Figure	 2.4B).	 In	
addition,	while	MHV	infection	of	BMM	significantly	induced	IFNβ	mRNA	expression	at	16	
hpi	 relative	 to	 mock	 infection,	 mRNA	 levels	 remained	 low	 in	 infected	 hepatocytes	
(Figure	 2.4C).	 Similar	 to	 the	 pattern	 of	Oas	mRNA	 expression,	 the	 basal	 levels	 of	 ISG	
mRNAs	 encoding	 a	 group	 of	 pattern	 recognition	 receptors,	 transcription	 factors	 and	
antiviral	genes	involved	in	the	host	response	to	viruses	(Figure	2.4D)	were	also	higher	in	
BMM	than	in	hepatocytes,	which	may	in	part	explain	the	weak	induction	of	IFNβ	mRNA	
in	 hepatocytes	 relative	 to	 BMM.	 The	 level	 of	 RNase	 L	 mRNA	 was	 not	 significantly	
different	in	BMM	and	hepatocytes	(data	not	shown).	
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II.3.iii	 MHV	replication	is	restricted	by	the	OAS-RNase	L	antiviral	pathway	in	microglia	
but	not	in	neurons,	astrocytes,	or	oligodendrocytes	
As	shown	above,	antagonism	of	RNase	L	is	not	required	for	efficient	MHV	replication	in	
the	brain.	Thus,	we	investigated	the	ability	of	each	of	the	major	CNS	cell	types	to	restrict	
A59	 and	 ns2H126R	 infection	 (Figure	 2.5).	 Primary	 cultures	 of	 hippocampal	 neurons,	
oligodendrocytes,	 astrocytes	 and	 microglial	 were	 each	 prepared	 as	 described	 in	 the	
Materials	 and	 Methods	 and	 previously	 (Bender,	 Phillips,	 Scott,	 &	 Weiss,	 2010;	
Feigenson,	 Reid,	 See,	 Crenshaw,	 &	 Grinspan,	 2009;	 Roth-Cross	 et	 al.,	 2008).	 Cultures	
were	 infected	 at	 an	 MOI	 of	 1	 PFU/cell	 and	 cells	 harvested	 at	 optimal	 times	 post	
infection	 for	 assessing	 growth	 kinetics	 of	 the	 virus	 in	 each	 cell	 type.	 There	 were	 no	
significant	differences	 in	 the	 titers	between	A59	and	ns2H126R	 in	neuron	 (Figure	2.5A),	
oligodendrocyte	(Figure	2.5B),	or	astrocyte	(Figure	2.5C)	cultures	at	the	times	examined.	
However,	in	microglia	(Figure	2.5D),	the	titer	of	ns2H126R	was	10-fold	lower	than	that	of	
A59	 at	 24	 hours	 post	 infection.	 Thus,	 like	 BMM,	 microglia	 preferentially	 restricted	
ns2H126R.	Furthermore,	ns2H126R	replicated	to	the	same	extent	as	A59	in	microglia	derived	
from	Rnasel-/-	mice	 (Figure	 2.5E),	 indicating	 that	 restriction	 of	 ns2	mutant	 virus	 in	 B6	
microglia	was	due	to	activation	of	RNase	L,	as	observed	previously	in	BMM	(Zhao	et	al.,	
2012;	Zhao	et	al.,	2011;	H.	Zhou,	Zhao,	&	Perlman,	2010).		
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II.3.iv	 Activation	of	RNase	L	activity	correlates	with	high	basal	and	induced	levels	of	
Oas	genes	and	IFN	signaling		
To	 investigate	 the	possibility	 that	 the	basal	 levels	of	 ISGs	contribute	 to	and/or	predict	
viral	 restriction,	we	quantified	 the	basal	mRNA	expression	 levels	of	Oas	 genes	 (Figure	
2.6A)	as	well	as	a	selection	of	other	ISGs	(Figure	2.6B)	in	the	major	cell	types	of	the	CNS	
parenchyma.	 The	 levels	 of	 basal	 ISG	mRNA	 (Figure	 2.6A&B)	were	 greater	 in	microglia	
than	in	other	CNS	cell	types,	as	might	be	expected	for	cells	of	macrophage	lineage.	The	
basal	 levels	 of	 ISG	 mRNAs,	 especially	 the	 Oas	 mRNAs,	 expressed	 in	 neurons	 and	
oligodendrocytes,	(Figure	2.6A),	were	low,	near	the	limit	of	detection	and	at	least	100	to	
1000-fold	 lower	 than	 in	 microglia,	 while	 astrocytes	 expressed	 intermediate	 mRNA	
levels.	Next,	we	examined	the	Oas	mRNA	 levels	after	viral	 infection	of	 these	CNS	cells	
types	(Figure	2.6C).	At	24	hours	post	infection	with	A59	or	ns2H126R,	the	Oas	mRNA	levels	
in	 neuron	 and	oligodendrocyte	 cultures	were	 still	 at	 or	 near	 the	 limit	 of	 detection	by	
qRT-PCR,	 indicating	 that	MHV	does	not	directly	 induce	 the	expression	of	Oas	 in	 these	
two	 cell	 types.	However,	 in	 astrocytes	 and	microglia,	 infection	 induced	 significant	 up-
regulation	of	Oas	mRNAs,	up	to	50-fold	for	Oas2.	However,	the	levels	in	astrocytes	were	
still	 10	 to	 100-fold	 lower	 than	 in	microglia.	 A59	 and	 ns2H126R	 elicited	 similar	 levels	 of	
induction.	
	
We	reasoned	that	the	lack	of	preferential	restriction	of	ns2H126R	in	CNS	cell	types	other	
than	microglia	was	due	to	sub-optimal	levels	of	OAS	leading	to	insufficient	production	of	
2-5A	and	 the	consequent	 lack	of	activation	of	RNase	L.	 In	order	 to	assess	directly	 the	
degree	 of	 RNase	 L	 activity	 induced	 during	 infection	 of	 CNS	 cells,	 we	 compared	 the	
extents	 of	 rRNA	 cleavage	 in	 neurons,	 oligodendrocytes,	 astrocytes,	 and	 microglia	
infected	at	24	hpi	with	either	ns2H126R	or	A59	(Figure	2.7A).	Bioanalyzer	analysis	of	RNA	
from	 infected	 cells	 showed	 that	 neither	 virus	 induced	 detectable	 rRNA	 cleavage	 in	
neurons,	 oligodendrocytes,	 or	 astrocytes,	 consistent	 with	 the	 lack	 of	 preferential	
restriction	 of	 ns2H126R	 in	 these	 cell	 types.	 In	 contrast,	 ns2H126R,	 but	 not	 A59,	 induced	
rRNA	cleavage	in	microglia.		
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We	had	observed	that	MHV	failed	to	induce	expression	of	type	I	IFN	in	many	cell	types	
(Roth-Cross	 et	 al.,	 2008;	 Roth-Cross,	 Martinez-Sobrido,	 Scott,	 Garcia-Sastre,	 &	Weiss,	
2007)	 and	 hypothesized	 that	 low	Oas	mRNA	 levels	 in	MHV	 infected	 primary	 cultures	
(Figure	6C)	could	be	attributed	 to	 insufficient	 IFN	production.	 Indeed,	analysis	of	 IFNβ	
mRNA	 levels	 by	 qRT-PCR	 showed	 that	 induction	 by	 both	 A59	 and	 ns2H126R	 was	more	
than	 100-fold	 greater	 in	microglia	 than	 in	 the	 other	 cell	 types	 tested	 (Figure	 2.7B).	 A	
bioassay	 for	 anti-viral	 activity	 (Figure	 2.7C)	 confirmed	 that	 both	 A59	 and	 ns2H126R	
induced	detectable	IFN	expression	in	microglia,	but	not	in	other	cell	types.	Thus,	these	
data	suggest	that	activation	of	 the	OAS-RNase	L	pathway	correlates	with	the	ability	of	
MHV	to	induce	IFN	production	and	underscores	the	requirement	for	simultaneous	type	I	
IFN	signaling	and	viral	infection	in	cells	with	low	basal	Oas	mRNA	levels.		
	
To	assess	the	effects	of	IFN	pretreatment	of	cells	on	ISG	mRNA	level	and	replication	of	
A59	and	ns2H126R,	primary	CNS	cultures	were	pretreated	with	IFNα	(100	U/ml).	At	24	h	
post	 treatment,	 Oas	 mRNA	 expression,	 as	 quantified	 by	 qRT-PCR,	 was	 significantly	
induced	 in	 all	 cell	 types	 as	 expected;	 the	 Oas1a	 and	 Oas2	 mRNAs	 levels	 in	
oligodendrocytes	 were	 similar	 to	 those	 in	 microglia	 (Figure	 2.8A).	 We	 then	 assessed	
replication	 of	 A59	 and	 ns2H126R	 in	 each	 cell	 type	 following	 IFN	 pretreatment.	 IFN	
pretreatment	severely	restricted	A59	replication	in	all	neural	cell	types,	up	to	1000-fold	
in	microglia,	100-fold	in	astrocytes	and	oligodendrocytes	and	10-fold	in	neurons	(Figure	
2.8B-E),	indicating	induction	of	IFN-dependent	antiviral	activities.	As	reported	previously	
(Zhao	 et	 al.,	 2011),	 ns2H126R	 displayed	 enhanced	 sensitivity	 to	 IFN	 pretreatment	 in	
microglia	similar	to	that	in	BMM	(Figure	2.8E),	implying	that	RNase	L	had	been	activated.	
In	 contrast,	 ns2H126R	 displayed	 similar	 sensitivity	 to	 IFN	 as	 A59	 in	 neurons,	
oligodendrocytes	and	astrocytes	(Figure	2.8B-D),	suggesting	that	RNase	L	had	not	been	
activated	despite	the	increase	in	Oas	levels	following	IFN	treatment.	
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II.3.v	 Several	other	viruses	also	fail	to	activate	RNase	L	in	astrocytes,	while	poly	(I:C)	
activates	RNase	L	in	astrocytes	and	oligodendrocytes		
In	order	to	determine	whether	the	failure	to	activate	RNase	L	in	neurons,	astrocytes	and	
oligodendrocytes	was	a	characteristic	of	these	cell	types	or	specific	to	MHV,	we	infected	
astrocytes	 with	 three	 other	 viruses,	 encephalomyocarditis	 virus	 (EMCV)	 (Hoskins	 &	
Sanders,	 1957),	 LaCrosse	 virus	 (LACV)	 (Thompson,	 Kalfayan,	 &	 Anslow,	 1965),	 and	
Sendai	virus	 (SeV)	 (Basler	et	al.,	2003).	 (EMCV	and	LACV	are	neurotropic,	while	SeV	 is	
pneumotropic.)	 We	 had	 found	 that	 RNase	 L	 restricted	 both	 SeV	 and	 EMCV	 in	
macrophages	(Zhao	et	al.,	2012)	and	that	SeV	induced	IFNβ	in	astrocytes	(Roth-Cross	et	
al.,	 2008).	 However,	 like	 A59	 and	 ns2H126R,	 EMCV,	 SeV,	 and	 LACV	 all	 failed	 to	 induce	
RNase	L	mediated	degradation	of	 rRNA	 in	astrocytes	 (Figure	2.9A),	 indicating	 that	 the	
failure	to	activate	RNase	L	in	astrocytes	is	not	specific	to	MHV.		
	
We	 next	 investigated	whether	 neurons	 or	 astrocytes,	 which	 did	 not	 exhibit	 RNase	 L-
mediated	 rRNA	 degradation	 in	 the	 context	 of	 viral	 infection,	 can	 regulate	 RNase	 L	
activity	in	response	to	poly	(I:C).	Poly	(I:C)	serves	as	a	surrogate	for	dsRNA	for	both	the	
induction	of	type	I	IFN	expression	and	the	activation	of	OAS.	We	treated	primary	neuron	
and	 astrocyte	 cultures	 with	 IFNα	 and	 transfected	 them	 with	 poly	 (I:C).	 RNA	 was	
extracted	 from	 treated	 cells	 6	 hours	 after	 poly	 (I:C)	 treatment	 and	 analyzed	 for	 the	
degradation	 of	 rRNA.	 rRNA	 degradation	 was	 evident	 in	 both	 cultures	 indicating	 that	
RNase	L	was	activated	(Figure	2.9B).	Thus,	astrocytes	and	neurons	have	the	potential	to	
upregulate	 RNase	 L	 activity,	 but	 this	 pathway	 is	 not	 activated	 during	 infection	with	 a	
variety	 of	 viruses	 including	 ns2H126R	mutant	 expressing	 an	 inactive	 phosphodiesterase	
(Figure	2.9B).			
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II.3.vi	 Cerebellum	and	spinal	cord	regions	activate	RNase	L	during	MHV	infection	
To	 assess	 infection	 of	 mouse	 brains	 during	 MHV	 infection,	 we	 intranasally	 or	
intracranally	 infected	 WT	 or	 Rnasel-/-	 with	 100,000	 PFU/mouse	 or	 200	 PFU/mouse,	
respectively.	 After	 five	 days	 of	 infection,	 we	 harvested	 different	 brain	 regions.	 These	
regions	 were	 grossly	 measured	 and	 labeled	 as	 the	 following:	 olfactory	 bulb,	 cortex,	
cerebellum,	brain	stem,	and	spinal	cord.	Virus	 replication	of	either	WT	A59	or	mutant	
strain	 from	these	mouse	brain	sections	were	compared.	 In	both	 the	 intranasal	 (Figure	
2.10A)	 and	 intracranial	 (Figure	 2.10C)	 experiments,	 the	 replication	 of	 each	 strain	 is	
similar	 between	 every	 brain	 region	 except	 in	 the	 spinal	 cord	 and	 the	 cerebellum.	 In	
these	 regions,	 mutant	 virus	 replication	 is	 significantly	 less	 than	 WT	 A59	 replication	
levels.	Furthermore,	this	replication	decrease	can	be	attributed	to	RNase	L	activation	as	
levels	 of	 replication	of	 the	mutant	 virus	 strain	 are	 not	 significantly	 different	 from	WT	
A59	 replication	 in	Rnasel-/-	mice	 (Figure	2.10B).	As	assessed	by	RNA	degradation,	only	
the	 cerebellum	 and	 spinal	 cord	 show	 observable	 degradation	 products	 during	 ns2	
mutant	infection	that	is	specific	to	RNase	L	(Figure	2.10E&F).	Additionally,	there	are	no	
significant	 differences	 in	 the	 basal	 mRNA	 expression	 levels	 of	 the	 Oas	 genes	 as	
measured	by	qPCR	(Figure	2.10D).	
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Figure	2.1.	Canonical	 type	 I	 IFN	 induction	and	signaling	pathway.	(Grey)	MHV	RNA	is	
recognized	 by	 MDA5	 leading	 to	 expression	 of	 IFNβ.	 IFNβ	 mediates	 transcription	 of	
antiviral	ISGs.	(Black)	OAS-RNase	L	pathway.	dsRNA	activates	OAS	which	synthesizes	2-
5A.	This	oligonucleotide	activates	RNase	L	 to	degrade	viral	and	cellular	RNA.	MHV	ns2	
can	degrade	2-5A.	
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Figure	2.2.	Replication	of	A59	and	ns2H126R	in	the	liver	and	the	brain	of	B6	and	Rnasel-/-	
mice.	 (A)	B6	and	Rnasel-/-	mice	were	 inoculated	 intracranially	with	200	PFU/mouse	of	
A59	or	ns2H126R	(n=5).	Mice	were	sacrificed	at	5	dpi,	brains	and	livers	harvested	and	virus	
titered	by	plaque	assay.	(B)	B6	and	Rnasel-/-	were	 inoculated	intranasally	with	200,000	
PFU/mouse	 of	 A59	 or	 ns2H126R	 (n=5).	Mice	 were	 sacrificed	 at	 5	 dpi,	 brains	 and	 livers	
harvested	and	virus	titered	by	plaque	assay.	(C)	RNA	was	extracted	from	the	livers	and	
brains	of	uninfected	mice	 (n=5);	 expression	 levels	of	Oas1a,	Oas2,	Oas3,	 and	RNase	 L	
mRNA	 were	 assessed	 by	 qRT-PCR.	 mRNA	 expression	 levels	 relative	 to	 β-actin	 mRNA	
were	 expressed	 as	 2–ΔCT,	 (ΔCT	 =	 CT（gene	 of	 interest）–CT（β-actin）).	 The	 data	 are	 from	 one	
representative	of	two	experiments	performed	and	are	shown	as	the	means	±	the	SEM.	
***,	p	<	0.001.		
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Figure	 2.3.	 Replication	 of	 A59	 and	 ns2H126R	 in	 primary	 hepatocytes.	 (A)	 Primary	
hepatocyte	or	(B)	BMM	cultures	were	infected	with	A59	or	ns2H126R	(1	PFU/cell);	at	the	
times	indicated	virus	was	titered	from	the	supernatant.	(C)	Primary	hepatocyte	cultures	
were	infected	with	A59	or	ns2H126R	(1	PFU/cell;	at	16	hpi,	cells	were	stained	with	DAPI	to	
locate	cellular	nuclei	(blue)	and	an	antibody	directed	against	MHV	nucleocapsid	protein	
to	 visualize	 virus	 (green).	 Cultures	 were	 examined	 under	 a	 Nikon	 Eclipse	 2000E-
Uﬂuorescence	microscope.	(D)	Primary	hepatocyte	cultures	were	treated	with	100	U/ml	
IFN	 for	 24	 hours,	 then	 infected	 with	 A59	 or	 ns2H126R	 and	 treated	 as	 in	 panel	 A.	
Hepatocytes	used	in	panels	A	and	D	were	prepared	from	the	same	mouse.	(E)	RNA	was	
extracted	from	infected	hepatocytes	and	BMM	(16	hours	post	infection)	and	ribosomal	
RNA	 (rRNA)	 degradation	 was	 assessed	 by	 Bioanalyzer.	 The	 data	 are	 from	 one	
representative	 of	 two	 experiments.	 The	 growth	 curves	 were	 performed	 in	 BMM	 in	
triplicate	and	in	hepatocytes	in	duplicate.	**,	p	<	0.01;	***,	p	<	0.001		
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Figure	 2.4.	Oas	 and	 IFNβ 	 mRNA	 expression	 in	 hepatocytes	 and	 BMM.	 (A)	RNA	was	
extracted	from	BMMs	and	hepatocytes	and	basal	levels	of	Oas1a,	Oas2	and	Oas3	mRNA	
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expression	were	quantified	by	qRT-PCR.	 (B)	Hepatocytes	and	BMM	were	infected	with	
A59	or	ns2H126R		(1	PFU/cell);	RNA	was	extracted	at	16	hpi	and	Oas1a	mRNA	expression	
was	quantified	by	qRT-PCR	(C)	Ifnβ1	mRNA	levels	were	quantified	by	qRT-PCR	using	the	
same	RNAs	as	 in	panel	B.	(D)	Basal	 levels	of	 ISG	mRNAs,	 including	MDA5,	STAT1,	 IRF7,	
IFIT1,	 and	 ISG15,	 were	 quantified	 in	 BMMs	 and	 hepatocytes	 by	 qRT-PCR.	 The	mRNA	
expression	levels	relative	to	β-actin	mRNA		were	expressed	as	2–ΔCT,	(ΔCT	=	CT（gene	of	interest
）–	CT（β-actin）).	The	data	are	from	one	representative	of	two	experiments,	performed	in	
triplicate	and	are	shown	as	the	means	±	the	SEM.	
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Figure	2.5.	Infection	of	primary	neural	cells	with	A59	and	ns2H126R.	Primary	cell	cultures	
of	 (A)	 neurons,	 (B)	 oligodendrocytes,	 (C)	 astrocytes,	 (D)	 microglia,	 and	 (E)	 Rnasel-/-	
microglia	were	 infected	with	A59	and	ns2H126R	 (1	PFU/cell).	Virus	was	titered	 from	the	
supernatant	at	the	times	indicated.	The	data	are	from	one	of	two	replicate	experiments	
(panel	 E,	 one	 experiment)	 performed	 in	 triplicate	 and	 are	 shown	 as	 the	means	 ±	 the	
SEM.	**,	p	<	0.01.		
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Figure	2.6.	Oas	mRNA	expression	in	primary	neural	cell	cultures.	(A)	RNA	was	extracted	
from	neurons,	oligodendrocytes,	 astrocytes	and	microglia	and	Oas1a,	Oas2,	 and	Oas3	
mRNA	 expression	 levels	 quantified	 by	 qRT-PCR.	 (B)	MDA5,	 RIG-I,	 STAT1,	 IRF-7,	 IFIT1,	
IFIT2	 and	 ISG15	mRNA	 levels	were	 quantified	 from	 the	 same	 RNAs	 as	 in	 panel	 A.	 (C)	
primary	cell	cultures	were	infected	with	A59	or	ns2H126R	or	mock	infected;	at	24	hpi	RNA	
was	extracted	and	Oas1a	mRNA	quantified.	mRNA	expression	 levels	relative	to	β-actin	
mRNA	were	 expressed	 as	 2–ΔCT,	 (ΔCT	=	CT（gene	of	 interest）–CT（β-actin）).	 The	 data	 are	 from	
one	 representative	 of	 two	 experiments	 performed	 in	 triplicate	 and	 are	 shown	 as	 the	
means	±	the	SEM.		
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Figure	2.7.	RNase	L	activity	and	IFNβ 	expression	following	infection	of	primary	neural	
cells.	(A)	Primary	neuron,	oligodendrocyte,	astrocyte	and	microglia	were	 infected	with	
A59	 and	 ns2H126R	 (1	 PFU/cell).	 RNA	 was	 harvested	 24	 hpi	 and	 analyzed	 for	 rRNA	
degradation	by	Bioanalyzer.	Positions	of	28S	and	18S	rRNA	are	indicated.	(B)	IFNβ	mRNA	
expression	was	quantified	in	RNAs	prepared	from	infected	cultures	as	in	panel	A.	mRNA	
expression	levels	relative	to	β-actin	mRNA	were	expressed	as	2–ΔCT	(ΔCT	=	CT（gene	of	interest)	
–	CT（β-actin）).	(C)	Supernatants	from	primary	CNS	cultures	as	in	panel	A	were	treated	with	
ultraviolet	 light	 and	 incubated	 with	 L2	 mouse	 ﬁbroblast	 cells	 for	 24	 h,	 followed	 by	
infection	with	NDV-GFP	 (1	 PFU/cell).	 As	 a	 positive	 control,	 L2	 cells	were	 treated	with	
IFNα	 alpha	 for	 24	h	 and	 then	 infected	with	NDV-GFP.	At	 24	hpi,	 cells	were	examined	
under	a	Nikon	Eclipse	2000E-Uﬂuorescence	microscope.	
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Figure	2.8.	Oas	mRNA	expression	and	virus	replication	in	primary	neural	cell	cultures	
following	IFNα 	treatment.	(A)	Primary	cell	cultures	were	treated	(or	mock	treated)	with	
100	U/ml	of	IFNα	for	24	hours.	RNA	was	extracted	and	expression	levels	of	Oas1a,	Oas2	
and	Oas3	were	 assessed	 by	 qRT-PCR.	 The	mRNA	 expression	 levels	 relative	 to	 β-actin	
mRNA	were	expressed	as	2–ΔCT,	(ΔCT	=	CT（gene	of	interest）–CT（β-actin）).	(B-E)	Primary	cultures	
were	pretreated	with	IFN	and	infected	with	A59	and	ns2H126R.	Virus	was	titered	from	the	
supernatants	at	the	indicated	times	(shown	in	black).	Also	shown	in	gray	are	the	titers	
from	untreated	 cultures,	 for	panels	B-D,	 the	 same	data	 from	Figure	2.5.	 The	data	are	
from	one	representative	of	 two	experiments	performed	 in	triplicate	and	are	shown	as	
the	means	±	the	SEM.	p	<0.05;	**,	p	<	0.01.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 46		
	
	
	 47		
	
Figure	 2.9.	 Activation	 of	 RNase	 L	 by	 other	 viruses	 and	 poly(I:C).	 (A)	 BMMs	 and	
astrocytes	were	infected	with	A59,	ns2H126R,	EMCV,	LACV	and	SeV	(1	PFU/cell	of	SeV	and	
LACV	 and	 0.1	 PFU/cell	 of	 EMCV).	 RNA	 was	 extracted	 from	 infected	 cells	 and	 rRNA	
degradation	 was	 assessed	 by	 Bioanalyzer.	 The	 positions	 of	 18S	 and	 28S	 rRNAs	 are	
indicated.	 Data	 shown	 are	 taken	 from	 three	 separate	 chips:	 1)	 BMM	 RNA;	 2)	 SeV	
infected	 cell	 RNA;	 3)	 mock,	 A59,	 ns2H126R,	 EMCV,	 and	 LACV	 infected	 cell	 RNA.	 (B)	
Astrocyte	and	neuron	cultures	were	treated	with	100	U/ml	IFN	for	24	h	and	transfected	
with	 10	 µg/ml	 pIC	 with	 Lipofectamine-2000.	 Six	 hours	 later,	 RNA	 was	 extracted	 and	
rRNA	 degradation	 was	 assessed	 by	 Bioanalyzer.	 Astrocyte	 and	 neuron	 RNA	 were	
analyzed	on	separate	chips.	The	data	are	from	one	representative	of	two	experiments.	
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Figure	 2.10.	 Activation	 of	 RNase	 L	 in	 isolated	 brain	 regions.	 (A)	 IN	A59	 and	ns2H126R	
infection	of	WT	mice	at	5	dpi	using	100,000	PFU/mouse	(B)	IN	A59	and	ns2H126R	infection	
of	Rnasel-/-	mice	at	5	dpi	using	100,000	PFU/mouse	 (C)	 IC	A59	and	ns2H126R	infection	of	
WT	mice	at	5	dpi	using	100,000	PFU/mouse	 (D)	Basal	Oas	mRNA	expression	 levels	 (E)	
rRNA	 degradation	 assay	 of	 WT	 mice	 brain	 regions	 with	 A59	 and	 ns2H126R	 at	 100,000	
PFU/mouse	5	dpi	 (F)	 rRNA	degradation	assay	of	Rnasel-/-	mice	brain	 regions	with	A59	
and	ns2H126R	at	100,000	PFU/mouse	5	dpi	
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III	
CHAPTER	THREE	
ACTIVATION	OF	THE	OAS–RNASE	L	PATHWAY	BY	MURINE	CORONAVIRUS	IN	
MACROPHAGES	IS	DEPENDENT	ON	BASAL	OAS	GENE	EXPRESSION	AND	IS	
INDEPENDENT	OF	VIRUS-INDUCED	INTERFERON	SECRETION	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
This	 chapter	 is	 taken	 from	 a	 2015	 published	 article	 in	 the	 Journal	 of	 Virology	 titled	
“Activation	of	RNase	L	by	murine	coronavirus	in	myeloid	cells	is	dependent	on	basal	Oas	
gene	expression	and	independent	of	virus-induced	interferon”	by	L.	Dillon	Birdwell,	Z.	
B.	Zalinger,	P.	W.	Wright,	R.	Elliott,	K.	M.	Rose,	R.	H.	Silverman,	and	S.	R.	Weiss	
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III.1	 ABSTRACT	
The	 oligoadenylate	 synthetase-ribonuclease	 L	 (OAS-RNase	 L)	 pathway	 is	 a	 potent	
interferon	 (IFN)	 induced	 antiviral	 activity.	 Upon	 sensing	 double	 stranded	 RNA,	 OAS	
produces	 2’,5’-oligoadenylates	 (2-5A),	 which	 activate	 RNase	 L.	 Murine	 coronavirus	
(MHV)	non-structural	protein	2	(ns2),	is	a	2’,5’-phosphodiesterase	(PDE)	that	cleaves	2-
5A,	 thereby	 antagonizing	 RNase	 L	 activation.	 PDE	 activity	 is	 required	 for	 robust	
replication	in	myeloid	cells	as	a	mutant	of	MHV	(ns2H126R)	encoding	an	inactive	PDE	fails	
to	 antagonize	 RNase	 L	 activation	 and	 replicates	 poorly	 in	 bone	 marrow	 derived	
macrophages	 (BMM)	 while	 ns2H126R	 replicates	 to	 high	 titer	 in	 several	 types	 of	 non-
myeloid	cells	as	well	as	in	IFN	receptor	deficient	(Ifnar1-/-)	BMM.	We	reported	previously	
that	myeloid	cells	express	significantly	higher	basal	 levels	of	OAS	transcripts	than	non-
myeloid	cells.	Here,	we	investigated	the	contributions	of	Oas	gene	expression,	basal	IFN	
signaling	and	virus-induced	 IFN	to	RNase	L	activation.	 Infection	with	ns2H126R	activated	
RNase	 L	 in	 Ifih1-/-	 BMM	 to	 a	 similar	 extent	 as	 in	 WT	 BMM	 despite	 the	 lack	 of	 IFN	
induction	in	the	absence	of	MDA5	expression.	However,	ns2H126R	failed	to	induce	RNase	
L	activation	in	BMM	treated	with	IFNAR1	blocking	antibody	as	well	as	in	Ifnar1-/-	BMM,	
both	 expressing	 low	 basal	 levels	 of	Oas	 genes.	 Thus,	 activation	 of	 RNase	 L	 does	 not	
require	virus-induced	IFN,	but	rather	correlates	with	adequate	levels	of	basal	Oas	gene	
expression,	maintained	by	basal	IFN	signaling.	Finally,	overexpression	of	RNase	L	is	not	
sufficient	to	compensate	for	inadequate	basal	OAS	levels.	
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III.2	 IMPORTANCE	
The	oligoadenylate-ribonuclease	L	(OAS-RNase	L)	pathway	is	a	potent	antiviral	activity.	
Activation	 of	 RNase	 L	 during	 murine	 coronavirus,	 MHV,	 infection	 of	 myeloid	 cells	
correlates	 with	 high	 basal	 Oas	 gene	 expression	 and	 is	 independent	 of	 virus-induced	
interferon	 secretion.	 Thus,	 our	 data	 suggest	 that	 cells	 with	 high	 basal	 Oas	 gene	
expression	 levels	 can	 activate	 RNase	 L	 and	 thereby	 inhibit	 virus	 replication	 early	 in	
infection	upon	exposure	to	viral	dsRNA,	before	the	induction	of	interferon	and	prior	to	
transcription	 of	 interferon	 stimulated	 antiviral	 genes.	 These	 findings	 challenge	 the	
notion	that	activation	of	 the	OAS/RNase	L	pathway	requires	virus	 to	 induce	type	 I	 IFN	
which	in	turn	upregulates	OAS	gene	expression	as	well	as	to	provide	dsRNA	to	activate	
OAS.	Our	data	further	suggest	that	myeloid	cells	may	serve	as	sentinels	to	restrict	viral			
replication	thus	protecting	other	cell	types	from	infection.	
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III.3	 INTRODUCTION		
The	 coronavirus	 mouse	 hepatitis	 virus	 (MHV)	 strain	 A59	 (A59)	 causes	 moderate	
hepatitis	and	mild	encephalitis	followed	by	chronic	demyelinating	disease	in	susceptible	
C57BL/6	 (B6)	mice	 (Lavi,	 Gilden,	Wroblewska,	 Rorke,	 &	Weiss,	 1984;	 Navas-Martin	 &	
Weiss,	2003;	Zhao,	Rose,	Elliott,	Van	Rooijen,	&	Weiss,	2011).	A59	 is	cleared	 from	the	
liver	and	central	nervous	system	primarily	by	the	T	cell	response	seven	to	ten	days	post	
infection	 (N.	 W.	 	 Marten	 et	 al.,	 2000;	 N.W.	 Marten,	 Stohlman,	 &	 Bergmann,	 2001).	
However,	type	I	interferon	(IFN)	production,	an	early	innate	immune	response,	is	crucial	
for	 early	 control	 of	MHV	 infection	 as	mice	 deficient	 in	 type	 I	 IFN	 receptor	 expression	
(Ifnar1-/-)	 uniformly	 die	 by	 two	 days	 after	 infection	 (Cervantes-Barragan	 et	 al.,	 2007;	
Ireland,	Stohlman,	Hinton,	Atkinson,	&	Bergmann,	2008;	Roth-Cross,	Bender,	&	Weiss,	
2008).	 Interestingly,	 A59	 fails	 to	 induce	 IFNα/β	 in	 most	 cell	 types,	 with	 the	 notable	
exception	of	myeloid	cells	(Roth-Cross	et	al.,	2008).	Induction	of	IFNα/β	in	macrophages	
and	 brain-resident	 microglia	 during	 MHV	 infection	 is	 dependent	 on	 sensing	 of	 viral	
dsRNA	 by	 the	 cytosolic	 RNA	 helicase,	 melanoma	 differentiation-associated	 gene	 5	
(MDA5)	 encoded	 by	 Ifih1	 (Kumagai,	 Takeuchi,	 &	 Akira,	 2008;	 Roth-Cross	 et	 al.,	 2008;	
Takeuchi	&	Akira,	2007).	IFN	induces	a	large	array	of	interferon-stimulated	genes	(ISGs),	
which	 include	 pattern	 recognition	 receptors	 (PRRs),	 signaling	molecules,	 transcription	
factors,	 and	 antiviral	 effectors	 (Dong	&	 Silverman,	 1995;	Durbin	 et	 al.,	 2000;	Malathi,	
Dong,	Gale,	&	Silverman,	2007;	Muller	et	al.,	1994;	Silverman,	2007b;	Zhou	et	al.,	1997).	
(Figure	 3.1,	 left	 side	 diagrams	 IFN	 synthesis	 and	 signaling	 in	 MHV	 infected	
macrophages).	The	only	other	source	of	type	I	IFN	during	A59	infection,	primarily	IFNα,	
is	 induced	 through	 a	 TLR7-dependent	 pathway	 in	 plasmacytoid	 dendritic	 cells	 (pDC)	
(Cervantes-Barragan	et	al.,	2012).	
	
Among	the	 ISGs	are	several	Oas	genes	encoding	proteins	 that	 function	as	nucleic	acid	
sensors	to	synthesize	2’,5’-oligoadenylates	(2-5A)	in	response	to	viral	dsRNA	in	the	host	
cytosol	 (Silverman,	 2007a).	 Mice	 express	 several	 OAS	 proteins	 that	 produce	 2-5A,	
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including	OAS1A/G,	OAS2,	 OAS3	 as	well	 as	 OASL2	 (Kakuta,	 Shibata,	 &	 Iwakura,	 2002;	
Mashimo	et	al.,	2003;	Silverman	&	Weiss,	2014).	The	2-5A	binds	to	and	activates	latent	
ribonuclease	 L	 (RNase	 L)	 by	 inducing	 conformational	 changes	 and	 subsequent	
dimerization	 (Dong	 &	 Silverman,	 1995;	 Silverman,	 2007b;	 Stark,	 Kerr,	 Williams,	
Silverman,	&	Schreiber,	1998).	RNase	L	activation	leads	to	restriction	of	virus	replication	
through	 the	 degradation	 of	 host	 and	 viral	 single	 stranded	 RNAs,	 inhibition	 of	 protein	
synthesis	and	finally	apoptosis	(J.	C.	Castelli	et	al.,	1998;	Castelli,	Wood,	&	Youle,	1998;	
Zhou	et	al.,	1997).	(Figure	3.1,	right	side	diagrams	activation	of	RNase	L).Interactions	of	
viruses	with	the	OAS-RNase	L	pathway	are	complex.	Many	viruses	encode	proteins	that	
inhibit	 this	pathway	 to	various	extents,	underscoring	 the	significance	of	 this	 system	 in	
restricting	viral	propagation	 (Han	et	al.,	2007;	Randall	&	Goodbourn,	2008;	Silverman,	
2007b;	Sorgeloos,	Jha,	Silverman,	&	Michiels,	2013;	Zhao	et	al.,	2012).	Among	the	most	
potent	of	these	inhibitors	is	the	A59	accessory	protein,	non-structural	protein	2	(ns2),	a	
2’,5’-phosphodiesterase	 (PDE)	 that	cleaves	2-5A	thereby	preventing	RNase	L	activation	
(Zhao	 et	 al.,	 2012).	 An	 A59	 mutant	 (ns2H126R)	 expressing	 an	 inactive	 PDE	 (due	 to	 an	
H126R	substitution	of	a	catalytic	histidine	residue)	fails	to	effectively	antagonize	RNase	
L,	 and	 consequently	 is	 attenuated	 for	 replication	 in	myeloid	 cells	 and	 in	 the	 livers	 of	
mice	(Zhao	et	al.,	2012).	
	
We	have	 found	 that	RNase	L	activation	 is	most	 robust	 in	myeloid	 lineage	cells,	where	
basal	Oas	gene	expression	levels	are	highest	compared	with	several	other	types	of	non-
myeloid	 primary	 cells	 including	 astrocytes,	 neurons,	 and	 oligodendrocytes,	 as	 well	 as	
transformed	cell	lines	(Zhao	et	al.,	2013).	Constitutive,	low	level	type	I	IFN	production	in	
the	 absence	 of	 infection	 maintains	 basal	 levels	 of	 expression	 of	 ISGs,	 including	 OAS	
(Sato,	 Taniguchi,	 &	 Tanaka,	 2001;	 Taniguchi	 &	 Takaoka,	 2001).	 It	 has	 been	 generally	
accepted	 that	 RNase	 L	 activation	 requires	 viral	 infection	 to	 both	 induce	 type	 I	 IFN	
production	which	 in	 turns	upregulates	OAS	gene	expression	and	to	provide	dsRNA	for	
activation	 of	 OAS	 to	 produce	 2-5A	 (Silverman,	 2007b).	 Thus,	 unlike	 most	 other	 IFN-
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induced	 activities,	 which	 can	 be	 stimulated	 in	 uninfected	 cells	 by	 paracrine	 IFN	
exposure,	RNase	L	can	be	activated	only	in	infected	cells.	
	
To	 further	 elucidate	 the	 cell-type	 dependent	 determinants	 of	 RNase	 L	 activation,	 we	
investigated	basal	Oas	mRNA	expression,	basal	IFN	signaling,	and	viral	 induction	of	IFN	
as	 three	potential	 contributors.	Our	data	 indicate	 that	RNase	 L	 activation	depends	on	
relatively	high	basal	mRNA	expression	 levels	of	Oas	 genes	 typical	of	myeloid	cells	and	
overexpression	 of	 RNase	 L	 is	 not	 sufficient	 to	 overcome	 insufficient	 levels	 of	 OAS.	
Furthermore,	RNase	L	activation	requires	adequate	basal	IFN	signaling	to	maintain	basal	
Oas	mRNA	expression.	However,	in	contrast	to	the	current	paradigm,	RNase	L	activation	
does	 not	 require	 IFN	 induction	 during	 virus	 infection	 of	 macrophages.	 These	 data	
suggests	 that	myeloid	cells	 can	activate	RNase	L	early	during	 infection	and	before	 the	
induction	of	IFN	and	thereby	limit	viral	spread	to	other	cell	types.		
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III.4	 OBSERVATIONS	
III.4.i	 Activation	of	RNase	L	during	ns2H126R	infection	of	dendritic	cells	correlates	with	
high	basal	Oas	gene	expression		
We	showed	previously	that	while	A59	antagonizes	the	OAS-RNase	L	pathway	in	myeloid	
lineage	cells,	including	brain-resident	microglia	and	liver-resident	Kupffer	cells	as	well	as	
bone	marrow	derived	macrophages	 (BMM)	(Roth-Cross	et	al.,	2009;	Zhao	et	al.,	2013;	
Zhao	 et	 al.,	 2012;	 Zhao	 et	 al.,	 2011),	 ns2H126R,	 a	 mutant	 expressing	 an	 inactive	
phosphodiesterase	 (PDE)	 fails	 to	 antagonize	 RNase	 L	 and	 consequently	 has	 severely	
restricted	 replication	 in	 these	 cell	 types.	 In	 contrast,	 replication	of	ns2H126R	 in	primary	
cell	types	including	neurons,	astrocytes,	and	hepatocytes	as	well	as	in	immortalized	cell	
lines	was	as	robust	as	A59	(Zhao	et	al.,	2013;	Zhao	et	al.,	2012;	Zhao	et	al.,	2011).	We	
investigated	whether	other	myeloid	cells,	such	as	dendritic	cells,	would	behave	similarly	
to	macrophages	upon	infection.	Thus,	we	compared	the	replication	of	A59	and	ns2H126R	
in	BMM	and	bone	marrow	derived	dendritic	cells	(BMDC),	derived	from	B6	(WT)	mice.	
As	observed	in	BMM	(Figure	3.2A)	(Zhao	et	al.,	2013;	Zhao	et	al.,	2012),	BMDC	(Figure	
3.2B)	also	restricted	mutant	virus	replication	by	100	fold	at	12	hours	(p<0.01)	and	1000	
fold	after	24	hours	post	infection	(p<0.001).		
	
We	next	 compared	 the	basal	 level	of	expression	of	Oas	 genes	 in	BMDC	with	 those	of	
BMM	and	neurons.	Using	real-time	quantitative	qRT-PCR,	we	quantified	basal	 levels	of	
expression	 of	 three	Oas	 genes	 that	 encode	 catalytically	 active	 OAS	 proteins,	Oas1a,	
Oas2,	and	Oas3,	in	WT	BMM	and	WT	BMDC	cultures	in	comparison	to	primary	neurons	
(Figure	3.2C),	the	latter	shown	previously	to	express	minimal	basal	levels	of	OAS	genes	
and	 to	 be	 unable	 to	 restrict	 replication	 of	 ns2H126R	 (Zhao	 et	 al.,	 2013).	 Oas	 mRNA	
expression	 levels	 in	 neurons,	 as	 expected,	 were	 under	 the	 limit	 of	 detection	 and	 in	
comparison	basal	mRNA	expression	levels	of	Oas1a,	Oas2,	and	Oas3	genes	in	WT	BMM	
and	WT	BMDC	were	1000	fold	greater	than	the	minimal	detectable	level	(Figure	3.2C).	
Levels	of	OAS1A,	OAS2,	OAS3,	and	RNase	L	were	similar	in	BMM	and	BMDC	culture,	as	
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assessed	 by	 immunoblotting	 (Figure	 3.2D).	 In	 order	 to	 compare	 RNase	 L	 activation	
during	 A59	 and	 ns2H126R	 infection,	 we	 monitored	 the	 state	 of	 ribosomal	 RNA	 (rRNA)	
cleavage	in	WT	BMM	and	BMDC	infected	with	either	ns2H126R	or	A59.	The	mutant	virus	
ns2H126R	 induced	 rRNA	 cleavage	 at	 9	 and	 12	 hours	 post	 infection	 in	 BMM	 and	 BMDC	
(Figure	3.2E).	 In	 contrast,	A59	did	not	 induce	 rRNA	cleavage,	 similar	 to	mock	 infected	
cells,	even	at	the	later	time	points.	Thus,	BMDC	behaved	similarly	to	BMM	in	activation	
of	 RNase	 L	 and	 restriction	 of	mutant	 virus	 and	 activation	 of	 RNase	 L	 correlated	with	
elevated	basal	levels	of	Oas	genes	(Zhao	et	al.,	2013).	
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III.4.ii	 Overexpression	of	RNase	L	does	not	overcome	low	basal	Oas	mRNA	expression	
to	promote	RNase	L	activation	by	ns2H126R	
	We	investigated	whether	the	level	of	RNase	L	expression	contributes	to	the	differences	
observed	between	 activation	 of	 RNase	 L	 and	ns2H126R	 replication	 in	myeloid	 and	non-
myeloid	cells.	Thus,	we	compared	BMM	and	astrocytes,	the	latter	previously	shown	to	
express	low	levels	of	Oas	genes	(Zhao	et	al.,	2013).	We	quantified	Rnasel	protein	levels	
by	 Western	 blot	 in	 BMM	 and	 astrocytes	 using	 cells	 derived	 from	 Rnasel-/-	mice	 as	 a	
negative	 control.	 There	were	no	 significant	differences	between	protein	expression	 in	
BMM	and	astrocytes	(Figure	3.3A).				
	
As	RNase	L	activation	is	dependent	on	the	production	of	2-5A,	we	investigated	whether	
overexpression	of	RNase	L	might	enable	the	low	level	of	2-5A	produced	by	cells	with	low	
basal	Oas	mRNA	expression	to	activate	RNase	L	to	degrade	rRNA	in	response	to	ns2H126R	
infection.	 For	 this	we	used	 a	murine	 3T3	 cell	 line	 (3T3/pLZ)	 that	 stably	 overexpresses	
human	RNase	L	from	a	cytomegalovirus	(CMV)	promoter	at	a	level	greater	than	100-fold	
that	of	endogenous	murine	RNase	L	cells	or	endogenous	human	RNase	L	 in	A549	cell.	
Human	RNase	L	was	previously	demonstrated	to	be	activated	in	3T3/pLZ	when	exposed	
to	2-5A.	(Zhou	et	al.,	1998).	Indeed,	RNase	L	protein	levels	are	much	greater	in	3T3/pLZ	
cells	 as	 compared	with	 A549	 (Figure	 3.3B).	 The	 A549	 cell	 line	 is	 derived	 from	human	
lung	epithelium	and	expresses	sufficient	endogenous	RNase	L	to	be	activated	upon	viral	
infection	(Cooper	et	al.,	2015).	However,	the	3T3/pLZ	cells	and	control	3T3/neo	lacking	
the	human	RNase	L	gene	expressed	a	relatively	low	level	of	Oas	mRNA	similar	to	that	of	
the	murine	L2	cell	line	(Zhao	et	al.,	2013)	(Figure	3.3D).	Upon	infection	of	3T3/pLZ	cells	
with	A59	and	ns2H126R,	both	viruses	 replicated	 to	high	 titer	as	 in	control	3T3/neo	cells	
(Figure	3.3D).	Furthermore,	RNase	L	was	not	activated	by	ns2H126R,	as	assessed	by	rRNA	
degradation	at	9	or	12	hours	post	infection	(Figure	3.3E).	Treatment	with	p(I:C)	with	or	
without	prior	IFN	treatment	did	activate	RNase	L	in	both	cell	types	demonstrating	that	
RNase	 L	 was	 active	 when	 OAS	 levels	 are	 induced.	 Thus,	 RNase	 L	 overexpression	 in	
3T3/pLZ	could	not	overcome	the	minimum	2-5A	threshold	needed	to	activate	RNase	L.		
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III.4.iii	 RNase	L	is	activated	in	the	absence	of	virus-induced	interferon	in	macrophages		
While	A59	induces	type	I	IFN	expression	in	only	a	limited	number	of	cell	types,	primarily	
myeloid	 cells	 (Roth-Cross	 et	 al.,	 2008;	 Roth-Cross,	 Martinez-Sobrido,	 Scott,	 Garcia-
Sastre,	&	Weiss,	2007),	the	activation	of	RNase	L	during	infection	(with	ns2H126R)	occurs	
only	in	the	same	limited	cell	types	(Roth-Cross	et	al.,	2008;	Roth-Cross	et	al.,	2007;	Zhao	
et	al.,	2013).	Thus,	we	investigated	whether	virus-induced	IFN	was	necessary	to	activate	
RNase	 L	 presumably	 by	 further	 upregulating	 the	 already	 high	 basal	 levels	 of	 OAS	
expression.	 IFN	 production	 during	 MHV	 infection	 of	 macrophages	 is	 dependent	 on	
MDA5	signaling	(Roth-Cross	et	al.,	2008).	Indeed,	using	a	sensitive	bioassay	for	antiviral	
activity	(Park	et	al.,	2003)	we	confirmed	that	both	A59	and	ns2H126R	infected	WT	BMM,	
secreted	 detectable	 antiviral	 activity	 at	 12	 and	 24	 hours	 post	 infection	 (Zhao	 et	 al.,	
2013),	while	 infected	MDA5	deficient	 (Ifih1-/-)	BMM	failed	 to	secrete	detectable	 levels	
(Figure	 3.4A).	We	 confirmed	 the	 presence	 of	 IFN	 in	 these	WT	 BMM	 supernatants	 by	
quantifying	the	level	of	IFNβ	secreted	at	12	hours	post	infection	by	ELISA.	In	WT	BMM,	
MHV	infection	elicited	detectable	but	low	levels	(20	to	25	pg/mL)	of	IFNβ	(Figure	3.4B),	
while	Ifih1-/-	BMM	cultures	did	not	produce	detectable	IFNβ.	Replication	of	ns2H126R	was	
100	 fold	 reduced	 at	 12	 hpi	 and	 1000	 fold	 attenuated	 after	 24	 hours	 in	 Ifih1-/-	
macrophages	 (Figure	 3.4D)	 compared	 to	 A59	 in	WT	 BMM	 (Figure	 3.4C)	 (Zhao	 et	 al.,	
2012)	 indicating	 that	 ns2H126R	replication	 is	 restricted	 in	 BMM	even	 in	 the	 absence	 of	
virus-induced	IFN	production.		
	
Consistent	with	the	above	findings,	we	observed	similar	levels	of	Oas	and	Rnasel	mRNA	
in	WT	 and	 Ifih1-/-	 BMM	 (Figure	 3.4E).	 In	 addition,	 the	 protein	 levels	 of	OAS1A,	OAS2,	
OAS3,	and	RNase	L	were	similar	between	BMM	cultures	derived	from	WT	or	Ifih1-/-	mice	
(Figure	3.4G).	There	is	some	variation	in	the		protein	levels	among	preparations	and	in	
this	particular	blot,	the	levels	appear	to	be	higher	for	MDA5	than		WT	BMM.	Also	shown	
are	 the	 levels	 of	OAS	protein	 in	 cells	 treated	with	 IFN.	 Interestingly	 the	 levels	 of	OAS	
proteins	are	not	much	greater	than	 in	untreated	cells.	Furthermore,	we	compared	the	
levels	of	other	 ISGs	 in	WT	and	 Ifih1-/-	BMM	and	found	 little	difference	 in	their	relative	
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mRNA	 expression	 levels,	 with	 the	 exception	 of	 MDA5,	 which	 as	 expected	 was	 not	
expressed	in	Ifih1-/-	BMM	cultures	(Figure	3.4F).	Finally,	RNase	L	activation	was	observed	
in	 both	 genotypes	 of	 BMM	by	 12	hours	 post	 infection	with	 ns2H126R	while	 it	was	 also	
evident	 at	 9	 hours	 in	WT	 cells.	 Thus,	 infection	with	 ns2H126R	 activated	 RNase	 L	 in	 the	
absence	of	virus-induced	IFN	(Figure	3.4H).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 63		
	
III.4.iv	 Basal	interferon	signaling	is	required	for	maintenance	of	adequate	Oas	mRNA	
levels	and	RNase	L	activation	in	macrophages		
Basal	IFN	signaling	is	necessary	to	maintain	basal	expression	of	ISGs,	which	enables	the	
cell	to	quickly	respond	to	infection	by	inducing	IFN	as	well	as	upregulating	antiviral	ISGs	
(Gough,	 Messina,	 Clarke,	 Johnstone,	 &	 Levy,	 2012).	 Indeed,	 we	 have	 reported	 much	
higher	levels	of	ISG	expression	in	myeloid	cells	that	are	able	to	induce	IFN	and	activate	
RNase	L	during	MHV	infection,	as	compared	to	other	cell	types	(Zhao	et	al.,	2013;	Zhao	
et	al.,	2011).	As	 in	the	data	shown	above	(Figure	3.4C)(Zhao	et	al.,	2011),	ns2H126R	was	
preferentially	restricted	compared	to	A59	in	WT	BMM	starting	at	9	hours	(p<0.05)	and	
100	fold	decreased	from	12	to	24	hours	after	infection	(p<0.01)	(Figure	3.5A).	However,	
replication	of	ns2H126R	was	fully	recovered	in	Ifnar1-/-	BMM	(Figure	3.5B).	
	
We	compared	the	expression	of	several	Oas	genes	in	WT	and	 Ifnar1-/-	BMM	and	found	
reduced	 expression	 of	Oas1a	 (p<0.01),	Oas2	 (p<0.001),	 and	Oas3	 (p<0.01)	mRNAs	 in	
Ifnar1-/-	 BMM,	 presumably	 due	 to	 loss	 of	 basal	 IFN	 signaling,	 but	 no	 significant	
difference	 in	 Rnasel	 mRNA	 expression	 (Figure	 3.5C).	 Furthermore,	 we	 compared	 the	
basal	protein	expression	levels	of	OAS1A,	OAS2,	and	RNase	L	in	BMM	derived	from	WT	
or	 Ifnar1-/-	mice.	OAS1A,	OAS2	and	OAS3	protein	was	undetectable	 in	cell	 lysates	from	
Ifnar1-/-	BMM	 cultures	 (Figure	 3.5D)	 with	 or	 without	 prior	 IFN	 treatment.	While	 OAS	
proteins	 are	 modestly	 induced	 by	 IFN	 treatment	 of	 WT	 BMM,	 RNase	 L	 protein	
expression	 is	 not	 dependent	 on	 IFNAR	 expression	 nor	 is	 it	 induced	 by	 IFN	 treatment.	
Basal	 expression	 levels	 of	 other	 ISG	 mRNA	 [including	 Ifih1	 (p<0.05),	 Ddx58	 (p<0.01),	
Ifit1,	 Ifit2,	 Isg15,	 and	 Irf7	 (p<0.0001)]	 were	 significantly	 decreased	 in	 the	 absence	 of	
IFNAR1	signaling	compared	to	WT	BMM.	Irf3	expression	level,	which	is	independent	of	
IFNAR1	signaling	(Sato	et	al.,	2000),	was	similar	in	WT	and	Ifnar1-/-	BMM.	Moreover,	Ifnb	
expression	 levels	were	 comparable	 in	 both	 genotypes	 and	near	 the	 limit	 of	 detection	
(Figure	3.5E).	Additionally,	 degradation	of	 rRNA	was	 assessed	 in	 lysates	 from	 infected	
BMM	cultures	at	9	and	12	hours	post	infection.	In	WT	BMM	cultures,	ns2H126R	infection	
induced	 rRNA	 degradation;	 however,	 in	 Ifnar1-/-	 BMM	 cultures,	 RNase	 L	 was	 not	
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activated	and	rRNA	degradation	was	not	observed	 (Figure	3.5F)	 supporting	 the	notion	
that	adequate	basal	levels	of	OAS	gene	expression	are	required	for	activation	of	RNase	L	
upon	virus	infection.		
	
We	hypothesized	that	the	difference	in	basal	ISG	expression	between	macrophages	and	
astrocytes	 could	 be	 at	 least	 in	 part	 due	 to	 the	 cell	 surface	 expression	 level	 of	 type	 I	
interferon,	 IFNAR1.	Cells	with	higher	 IFNAR1	surface	expression	might	promote	higher	
basal	IFN	signaling	and	ISG	levels	and	therefore	be	more	likely	to	activate	RNase	L	in	the	
presence	of	dsRNA	early	during	ns2H126R	infection.	To	assess	surface	IFNAR1	expression	
on	BMM,	microglia,	and	astrocytes,	BMM	and	primary	astrocyte/microglia	cultures	were	
stained	 for	 identifying	markers	 and	 IFNAR1	 and	 then	 analyzed	 by	 flow	 cytometry.	 As	
astrocytes	 displayed	 a	 larger	 range	 in	 size	 as	 compared	 to	 macrophages	 (data	 not	
shown),	 we	 applied	 a	 size	 normalization	 algorithm	 to	 determine	 density	 of	 surface	
IFNAR1.	 Using	 previously	 described	 methods	 (Knijnenburg	 et	 al.,	 2011)	 fluorescence	
intensity,	 dependent	 on	 both	 surface	 IFNAR1	 density	 and	 cell	 surface	 area,	 was	
normalized	 by	 cell	 size	 to	 enable	 comparison	 of	 extent	 of	 relative	 IFNAR1	 expression	
across	cell	types.	Surface	density	of	IFNAR1	was	higher	in	microglia	and	BMM	compared	
to	 astrocytes	 (Figure	 3.5G),	 perhaps	 contributing	 to	 the	 higher	 extent	 of	 basal	 ISGs	
detected	in	myeloid	cells.		
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III.4.v	 Modulation	 of	 surface	 IFNAR1	 activity	 regulates	 basal	Oas	mRNA	 expression	
and	RNase	L	activation		
To	complement	the	 infections	 in	 Ifnar1-/-	BMM	and	to	further	explore	the	relationship	
between	IFN	signaling,	basal	Oas	gene	expression	and	activation	of	RNase	L,	we	aimed	
to	modulate	IFNAR1	activity	on	WT	BMM	such	that	adequate	basal	IFN	signaling	would	
be	maintained	 but	 the	 cells	 would	 not	 be	 capable	 of	 further	 upregulating	 ISGs	 upon	
infection.	We	used	a	monoclonal	antibody	(MAR1-5A3)	specific	for	the	IFNAR1	subunit	
of	the	murine	IFN	receptor	that	binds	to	cell	surface	IFNAR1	and	blocks	ligand-induced	
intracellular	receptor	signaling	and	induction	of	ISGs	(Fenner	et	al.,	2006;	Lazear,	Pinto,	
Vogt,	 Gale,	 &	 Diamond,	 2011;	 Pinto	 et	 al.,	 2011;	 Samuel	 et	 al.,	 2006).	 Following	 one	
hour	 of	 2	µg/mL	 antibody	pretreatment	 of	WT	BMM,	 there	was	no	 increase	 in	Oas1,	
Oas2	or	Oas3	mRNA	expression	 following	 infection,	 and	 the	basal	 levels	 of	mRNAs	 in	
mock	infected	cells	were	the	same	as	in	“no	mAb”	controls	(Figure	3.6A-C).	Other	ISGs,	
for	example	Ifit1,	also	failed	to	be	induced	following	infection	(data	not	shown).	Under	
these	conditions,	RNase	L	activity	was	still	activated	by	infection	with	ns2H126R	at	9	and	
12	hours	post	 infection	 (Figure	3.6G)	 resulting	 in	 restriction	of	viral	 replication	 (Figure	
3.6E).	Thus,	with	a	one	hour	pretreatment	with	2	µg/mL	of	antibody,	basal	mRNA	levels	
of	OAS	genes	are	maintained	and	BMM	retain	the	ability	 to	restrict	MHV	and	activate	
RNase	L,	in	the	absence	of	upregulation	of	Oas	expression	levels.	However,	the	use	of	a	
higher	 dose	 of	 antibody	 (5	 µg/mL)	 recapitulated	 the	 phenotype	 observed	 in	 Ifnar1-/-	
BMM	 in	 that	 basal	 levels	 of	 Oas	 mRNA	 expression	 in	 mock	 infected	 mice	 were	
decreased	approximately	10	fold	(Figure	3.6A-C;	compare	mock	infected,	5	µg/mL	mAb	
treated	 to	mock	 infected,	no	mAb	 treatment).	 In	addition,	Oas	mRNA	 levels	were	not	
induced	by	 infection	 and	 activation	 of	 RNase	 L	 did	 not	 occur	 as	 assessed	by	 an	 rRNA	
degradation	 assay	 (Figure	 3.6G)	 and	 replication	 of	 ns2H126R	 was	 no	 longer	 restricted	
(Figure	 3.6F).	 It	 is	 important	 to	 note	 that	 treatment	 of	 cells	 with	 an	 isotype	 control	
antibody	 had	 no	 effect	 on	 replication	 of	 A59	 or	 ns2H126R	 and	 that	 the	 replication	 of	
ns2H126R	was	restricted	following	treatment	with	 isotype	control	antibody	(Figure	3.6F)	
indicating	 the	effects	were	 specific	 for	 IFNAR1	 (Figures	3.6E&F).	 Thus,	 consistent	with	
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our	observations	from	infection	of	Ifnar1-/-	and	Ifih1-/-	BMM	(Figures	3.4&5)	activation	of	
RNase	L	correlated	with	Oas	gene	basal	level	of	expression	and	did	not	require	further	
upregulation	during	infection.	
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Figure	3.1.	OAS-RNase	L	pathway.	Interferon	induction	and	signaling	(left	side)	(1)	Viral	
dsRNA	is	produced	during	virus	replication	(2)	dsRNA	is	sensed	by	PRRs	such	as	MDA5,	
initiating	 a	 signaling	 pathway	 leading	 to	 (3)	 transcription,	 translation	 and	 secretion	of	
IFNα/β.	 (4)	 Autocrine	 and	 paracrine	 IFN	 signaling	 through	 the	 interferon	 receptor	
(IFNAR1)	(5,6)	stimulates	the	expression	of	ISGs.	RNase	L	activation	(right	side)	(7)	OAS	
sense	 viral	 dsRNA	 and	 synthesize	 2-5A	 (8)	 2-5A	 binds	 to	 RNase	 L	 inducing	 its	
dimerization	and	subsequent	activation.	(9)	RNase	L	degrades	RNA.		
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Figure	 3.2.	 Activation	 of	 RNase	 L	 by	 ns2H126R	during	 infection	 of	 BMM	 and	 BMDC	
cultures.	 (A)	 BMM	 and	 (B)	 BMDC	 cultures	 were	 infected	 with	 A59	 or	 ns2H126R	(1	
PFU/cell)	 and	 at	 the	 times	 indicated,	 the	 virus	 titer	 was	 determined	 by	 plaque	 assay	
from	the	supernatant.	The	data	are	pooled	from	two	independent	experiments	carried	
out	in	triplicate	and	shown	as	the	means	±	SEM.	*,	P<	0.05;	**,	P	<	0.01;	***,	P	<	0.001.	
(C)	 RNAs	 was	 extracted	 from	 infected	 BMM,	 BMDC	 and	 neuron	 cultures	 and	
Oas1a,	Oas2,	and	Oas3	mRNA	expression	was	quantified	by	qRT-PCR.	Expression	 levels	
of	mRNA	relative	to	β-actin	mRNA	are	expressed	as	2−ΔCT,	where	∆CT	=	(CT,	Target	Gene	-	CT,	β-
actin).	The	dashed	line	designates	the	lower	limit	of	detection.	These	data	are	from	one	
representative	experiment	of	two,	each	performed	in	triplicate.	(D)	Protein	lysates	from	
BMM	 and	 BMDC	 were	 electrophoresed	 in	 acrylamide	 gels	 and	 then	 probed	 with	
antibodies	 against	 OAS1A,	 OAS2,	 OAS3,	 RNase	 L	 (mAb),	 and	 GAPDH.	 (E)	 RNA	 was	
extracted	 from	 infected	BMM	and	BMDC	cultures	at	9	and	12	hours	post	 infection	as	
well	as	cultures	12	hours	post	mock	infection	and	rRNA	degradation	was	assessed	with	
an	Agilent	2100	Bioanalyzer.	The	positions	of	28S	and	18S	rRNA	are	indicated.		
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Figure	3.3.	Overexpression	of	RNase	L	is	not	sufficient	to	overcome	low	OAS	levels	to	
promote	RNase	L	degradation.	(A)	Proteins	were	extracted	from	WT	and	Rnasel-/-	BMM	
and	 astrocytes,	 electrophoresed	 in	 polyacrylamide	 gels	 and	 probed	 by	 Western	 blot	
with	 antibodies	 directed	 against	 RNase	 L	 (rabbit	 polyclonal)	 and	 β-tubulin.	 BMM	 and	
astrocyte	 cell	 lysates	were	 electrophoresed	 on	 the	 same	 gel	 and	 blotted	 at	 the	 same	
time	 and	 intervening	 lanes	 were	 removed	 and	 replaced	 by	 space	 between	 samples.	
(B)	Proteins	 were	 extracted	 from	 human	 A549	 and	 murine	 3T3/pLZ	 cells,	
electrophoresed	 in	 polyacrylamide	 gels	 and	 probed	 by	 Western	 blot	 with	 antibodies	
directed	against	human	RNase	L	and	human	β-tubulin.	(C)	RNA	was	extracted	from	L2,	
3T3/pLZ,	3T3/neo,	and	BMM	cultures	and	basal	expression	 levels	of	Oas	mRNAs	were	
quantified	by	qRT-PCR.	In	A	and	C,	mRNA	expression	levels	relative	to	β-actin	mRNA	are	
expressed	as	2−ΔCT,	where	∆CT	=	(CT,	Target	Gene	-	CT,	β-actin).	Data	are	from	one	representative	
experiment	 of	 two	 each	 performed	 in	 triplicate	 except	 for	 3T3/neo	 data.	 The	 dashed	
line	designates	the	lower	limit	of	detection.	(D)	3T3/pLZ	and	3T3/neo	cells	were	infected	
with	 A59	 or	 ns2H126R	(1	 PFU/cell)	 and	 at	 the	 times	 indicated,	 the	 virus	 titer	 was	
determined	 by	 plaque	 assay	 from	 the	 supernatant.	Data	 are	 pooled	 from	 two	
independent	experiments	(3T3/pLZ)	or	from	one	experiment	(3T3/neo)	each	performed	
in	 triplicate.	 (E)	Cells	 were	 pretreated	 with	 100	 units/mL	 of	 IFNα	 for	 4	 hours	 and/or	
transfected	with	1	ug/mL	p(I:C)	or	infected	as	in	panel	E.	RNA	was	extracted	at	9	and	12	
hours	post	 transfection	or	post	 infection	and	 rRNA	degradation	was	 assessed	with	 an	
Agilent	2100	Bioanalyzer.	The	18S	and	28S	rRNAs	are	indicated.		
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Figure	 3.4.	Infection	 of	 Ifih1-/-	macrophages	 with	 A59	 and	 ns2H126R.	(A)	 WT	 or	Ifih1-/-
BMM	cultures	were	either	mock	infected	or	infected	with	A59	or	ns2H126R	(1	PFU/cell).	
At	12	hours	post	 infection,	supernatants	were	treated	with	UV	light	to	 inactivate	virus	
and	incubated	with	L2	mouse	fibroblasts	for	24	h,	followed	by	infection	with	NDV-GFP	(1	
PFU/cell).	 As	 a	 positive	 control,	 L2	 cells	 were	 treated	 with	 IFNα	 for	 24	 h	 and	 then	
infected	with	NDV-GFP.	At	12	or	24	hours	post	infection,	cells	were	fixed	and	examined	
for	 enhanced-GFP	expression	by	microscopy.	 (B)	 Supernatants	 taken	at	 12	hours	post	
infection	from	the	same	mock	infected	or	A59	and	ns2H126R	infected	WT	and	Ifih1-/-	BMM	
cultures	were	 analyzed	 by	 ELISA	 for	mouse	 IFNβ	 by	 VeriKine	 kit.	 Limit	 of	 detection	 is	
indicated	by	dashed	line.	Data	are	from	one	representative	experiment	of	two.	(C)	WT	
BMM	and	(D)	Ifih1-/-	BMM	cultures	were	infected	with	A59	and	ns2H126R	(1	PFU/cell)	and	
at	 the	 times	 indicated,	 the	 virus	 titer	 was	 determined	 by	 plaque	 assay	 from	 the	
supernatant.	 Data	 are	 pooled	 from	 two	 independent	 experiments	 performed	 in	
triplicate	and	shown	as	the	means	±	SEM.	*,	P	<	0.05;	**,	P	<	0.01;	***,	P<	0.001.	(E	and	
F)	mRNA	expression	levels	relative	to	β-actin	mRNA	are	expressed	as	2−ΔCT,	where	∆CT	=	
(CT,	Target	Gene	-	CT,	β-actin).	Dashed	line	designates	the	lower	limit	of	detection.	Data	shown	
are	pooled	from	two	independent	experiments	each	performed	in	triplicate	and	shown	
as	the	means	±	SEM.	*,	P	<	0.05;	**,	P	<	0.01;	***,	P<	0.001.	(G)	Proteins	were	extracted	
from	WT	and	Ifih1-/-	BMM	and	probed	by	Western	blot	with	antibodies	directed	against	
OAS1A,	OAS2,	OAS3,	RNase	L	(mAb),	and	GAPDH.	(H)	RNA	was	extracted	from	infected	
WT	 and	 Ifih1-/-	BMM	 cultures	 at	 9	 and	 12	 hours	 post	 infection	 as	well	 as	 cultures	 12	
hours	 post	mock	 infection	 and	 rRNA	 degradation	 was	 assessed	 with	 an	 Agilent	 2100	
Bioanalyzer.	The	28S	and	18S	rRNAs	are	indicated.		
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Figure	3.5.	RNase	L	 is	not	activated	during	 infection	of	 Ifnar1-/-	macrophages.	(A)	WT	
and	 (B)	 Ifnar1-/-	 BMM	cultures	were	 infected	with	A59	 or	 ns2H126R	(1	 PFU/cell)	 and	 at	
times	 indicated	 virus	 titered	 by	 plaque	 assay	 from	 the	 supernatant.	 Data	 are	 pooled	
from	two	independent	experiments	performed	in	triplicate	and	shown	as	the	means	±	
SEM.	*,	P	<	0.05;	**,	P	<	0.01;	***,	P<	0.001.	(C)	RNA	was	extracted	from	uninfected	WT	
and	 Ifnar1-/-	BMM	cultures	and	Oas1a,	Oas2,	Oas3,	and	Rnasel	mRNA	were	quantified	
by	 qRT-PCR.	mRNA	expression	 levels	 relative	 to	 β-actin	mRNA	 are	 expressed	 as	 2−ΔCT,	
where	 ∆CT	 =	 (CT,	 Target	 Gene	 -	 CT,	 β-actin).	 The	 dashed	 line	 designates	 the	 lower	 limit	 of	
detection.	(D)	Protein	 was	 extracted	 from	 WT	 and	 Ifnar1-/-	 BMM	 cultures,	
electrophoresed	 in	 polyacrylamide	 gels	 and	 probed	 with	 antibodies	 directed	 against	
OAS1A,	 OAS2,	 OAS3,	 RNase	 L	 (mAb),	 and	 GAPDH.	 (E)	RNA	 was	 extracted	 from	
uninfected	WT	and	 Ifnar1-/-	BMM	cultures	and	ISG	mRNA	were	quantified	by	qRT-PCR.	
Expression	levels	of	mRNA	relative	to	β-actin	mRNA	are	expressed	as	2−ΔCT,	where	∆CT	=	
(CT,	Target	Gene	-	CT,	β-actin).	The	dashed	line	designates	the	lower	limit	of	detection	Data	are	
from	one	representative	experiment	of	two,	each	performed	with	triplicate	and	shown	
as	the	means	±	SEM.	*,	P	<	0.05;	**,	P	<	0.01;	***,	P<	0.001;	****,	P	<	0.0001.	(F)	RNA	
was	extracted	from	BMM	cultures	at	9	and	12	hours	post	infection	as	well	as	cultures	12	
hours	 post	mock	 infection	 and	 rRNA	 degradation	 was	 assessed	 with	 an	 Agilent	 2100	
Bioanalyzer.	 The	28S	and	18S	 rRNAs	are	 indicated.	 (G)	Astrocytes	and	microglia,	 from	
mixed	 glial	 cultures,	 and	 macrophages,	 from	 bone	 marrow	 derived	 cultures,	 were	
stained	 with	 cell	 type	 specific	 antibodies,	 as	 well	 as	 for	 IFNAR1,	 analyzed	 by	 flow	
cytometry	with	an	LSR	II	(Becton	Dickinson),	and	the	resulting	data	were	analyzed	using	
FlowJo	 Software	 (Treestar).	 Astrocytes	 (GFAP+CD11b-F4/80-),	 microglia	 (GFAP-
CD11b+F4/80+),	 and	 macrophages	 (GFAP-CD11b+F4/80+)	 were	 assessed	 for	 surface	
expression	 of	 IFNAR1.	 Data	 are	 from	 one	 representative	 experiment	 of	 two,	 each	
performed	with	triplicate	cultures	of	each	cell	type.		
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Figure	3.6.	Activation	of	RNase	L	activity	in	BMM	treated	with	IFNAR1	blocking	MAR1-
5A3	mAb.	WT	BMM	were	treated	with	2	µg/mL	or	5	µg/mL	MAR1-5A3	IFNAR1	blocking	
mAb	or	no	mAb	or	isotype	control	Ab	(panels	E	and	F	only)	for	1	hour	before	infection	or	
mock	infection	with	A59	or	ns2H126R	(1	PFU/cell).	RNA	was	extracted	from	cells	at	0	time	
post	mock	infection	and	12	hours	post	virus	infection.	Expression	levels	of	(A)	Oas1a,	(B)	
Oas2,	 and	 (C)	 Oas3	mRNA	 were	 quantified	 by	 qRT-PCR.	 Levels	 of	 mRNA	 expression	
relative	to	β-actin	mRNA	are	expressed	as	2−ΔCT,	where	∆CT	=	(CT,	Target	Gene	-	CT,β-actin).	The	
dashed	 line	 designates	 the	 lower	 limit	 of	 detection.	 These	 data	 are	 pooled	 from	 two	
independent	experiments,	each	performed	 in	triplicate	and	are	shown	as	the	means	±	
SEM.	 Values	 for	mock	 infected,	 5	 µg/mL	mAb	 treated	 are	 significantly	 different	 from	
mock	 infected,	0	mAb	or	2	µg/mL	mAb	treated,	*,	P	<0.05;	Supernatants	 from	A59	or	
ns2H126R	 infected	 BMM	 cultures	 pretreated	 with	 (D)	 no	 mAb,	 (E)	 2	 µg/mL	 IFNAR1	
blocking	mAb	(solid	line)	or	istoype	control	Ab	(dotted	line),	and	(F)	5	µg/mL	of	IFNAR1	
blocking	mAb	 (solid	 line)	or	 istotype	control	Ab	 (dotted	 line)	were	 titered	 for	 virus	by	
plaque	assay.	Data	are	pooled	from	three	independent	experiments	using	MAR1-5A3	or	
one	 experiment	 using	 isotype	 control	 antibody,	 each	 performed	 in	 triplicate	 and	 are	
shown	as	the	means	±	SEM.	*,	P	<	0.05;	**,	P	<	0.01.	(G)	RNA	was	extracted	at	9	and	12	
hours	 post	 infection	 from	 BMM	 cultures	 that	 had	 been	 pretreated	 with	 mAb	 as	
indicated,	and	 rRNA	degradation	was	assessed	with	a	Bioanalyzer.	28S	and	18S	 rRNAs	
are	 indicated.	 RNA	 from	 mock	 infected	 cultures	 appeared	 similar	 to	 that	 from	 A59	
infected	cells	(not	shown)	as	in	Figures	3.2E,	3.3F,	3.4H,	and	3.5F.	
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IV	
CHAPTER	FOUR	
CONCLUSIONS	AND	GENERAL	DISCUSSION	
	
Previous	 studies	 from	 our	 lab	 (Zhao	 et	 al.,	 2012;	 Zhao,	 Rose,	 Elliott,	 Van	 Rooijen,	 &	
Weiss,	2011b)	and	others	(Daffis,	Samuel,	Keller,	Gale,	&	Diamond,	2007;	Ida-Hosonuma	
et	al.,	2005;	Ida-Hosonuma	et	al.,	2003)	have	shown	that	basal	as	well	as	virus-	and/or	
IFN-induced	 levels	of	 ISG	expression	are	 important	determinants	of	permissiveness	 to	
viral	infection	and	the	resulting	cellular	and	organ	tropism.	We	have	reported	previously	
that	 the	 basal	 expression	 levels	 of	 mRNAs	 encoding	 ISG	 proteins,	 including	 MDA5,	
STAT1	and	other	molecules	that	crucial	for	recognizing	viral	 invasion	and	producing	an	
antiviral	 environment,	 were	 greater	 in	 the	 liver	 than	 in	 the	 CNS	 and	 also	 higher	 in	
myeloid	 cells	 than	 in	 other	 cell	 types	 (Zhao	 et	 al.,	 2012;	 Zhao	 et	 al.,	 2011b;	 H.	 Zhou,	
Zhao,	&	Perlman,	2010).	Similarly,	microglia	 isolated	 from	naïve	mice	or	mice	 infected	
with	an	attenuated	neurotropic	strain	of	MHV	expressed	higher	basal	and	induced	levels	
of	ISG	mRNA	than	did	oligodendrocytes	(Kapil,	Butchi,	Stohlman,	&	Bergmann,	2012).	
We	 show	 here	 that	 the	 expression	 levels	 of	Oas	 mRNAs	 follow	 similar	 patterns.	 The	
basal	mRNA	expression	levels	of	the	active	Oas	species	Oas1a,	Oas2,	and	Oas3	are	100	
to	1000-fold	higher	 in	the	 liver	 than	 in	the	brain,	suggesting	that	 the	 low	 level	of	OAS	
expression	in	the	brain	precludes	activation	of	the	OAS-RNase	L	pathway	and	allows	the	
replication	of	ns2H126R.	 Similarly	 among	 cell	 types	examined,	myeloid	 cells	 express	 the	
highest	 basal	 levels	 of	Oas	 and	 are	 the	 only	 cell	 types	 thus	 far	 tested	 in	which	MHV	
needs	an	enzymatically	active	ns2	to	ensure	efficient	replication.	Bone	marrow	dendritic	
cells,	also	of	myeloid	lineage,	preferentially	restrict	ns2H126R	(Figure	3.2B).	
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Compared	 to	myeloid-derived	 cell	 types,	 after	 infection	with	A59	or	ns2H126R,	 neurons	
and	 oligodendrocytes	 showed	 little	 increase	 in	Oas	 mRNA	 expression,	 while	 the	Oas	
expression	levels	in	astrocytes	were	significantly	upregulated,	although	not	to	the	levels	
in	 myeloid	 cells	 (Figure	 2.6C).	 Virus	 replication	 in	 oligodendrocytes	 and	 astrocytes	 is	
robust,	with	titers	similar	to	those	produced	in	microglia	or	in	L2	cell	lines.	Indeed,	A59	
causes	 cytopathic	 effect	 (syncytia)	 in	 primary	microglia	 and	 astrocyte	 cultures.	While	
virus	remains	more	cell-associated	in	neurons,	it	appears	to	spread	rapidly	cell-to-cell	in	
infected	 primary	 neuronal	 cultures	 (Bender,	 Phillips,	 Scott,	 &	Weiss,	 2010).	 Thus,	 the	
lack	 of	 activation	 of	 RNase	 L	 is	 not	 due	 to	 a	 low	 percentage	 of	 infected	 cells.	
Pretreatment	 of	 these	 cultures	with	 IFNα	 to	 induce	 the	 expression	 of	Oas	mRNAs	 as	
might	 occur	 in	 vivo	 (Figure	 2.7B-E)	 did	 not	 produce	 activation	of	 RNase	 L	 in	 any	non-
myeloid	 cell	 type	 (data	 not	 shown)	 including	 hepatocytes,	 and	 consequently	 all	
permitted	 ns2H126R	 to	 replicate	 similarly	 to	 A59.	 Interestingly,	 other	 interferon-
stimulated	 antiviral	 activities	were	 clearly	 effective	 in	 all	 cell	 types,	 as	 the	 viral	 titers	
were	 lower	 in	 pretreated	 cultures	 by	 approximately	 100-fold	 for	 astrocytes	 and	
oligodendrocytes	and	to	a	lesser	extent	for	neurons	as	compared	to	about	1000-fold	in	
microglia.	 Similarly,	West	 Nile	 virus	 replication	was	 significantly	 less	 restricted	 by	 IFN	
pretreatment	 of	 primary	 neuronal	 cultures	 as	 compared	 with	 macrophages	 and	 this	
correlated	with	relatively	low	levels	of	ISG	expression	in	neuronal	cultures	(Daffis	et	al.,	
2007;	Daffis,	Suthar,	Gale,	&	Diamond,	2009).		
	
In	 order	 to	 investigate	whether	 introduction	 of	MHV	 through	 a	 less	 artificial	 route	 of	
infection	would	induce	a	protective	RNase	L	response,	we	inoculated	virus	intranasally.	
Olfactory	bulb	neurons	may	be	specialized	to	control	viruses,	as	they	are	most	exposed	
to	 environmental	 factors.	 In	 addition,	 they	 continue	 to	 replicate	 in	 vivo	 in	 adult	mice	
(Cowan	&	Roskams,	2002)	and	thus	may	tolerate	higher	levels	of	ISG	expression.	Indeed,	
ISG	 induction	 has	 been	 reported	 in	 the	 olfactory	 bulb,	 most	 likely	 in	 neurons,	 in	
response	 to	 vesicular	 stomatitis	 virus	 (VSV)	 (Detje	 et	 al.,	 2009;	 Lang	 et	 al.,	 2010).	
Similarly,	 VSV	 infection	 was	 restricted	 by	 the	 IFN-stimulated	 gene	 product	 of	 IFIT2	
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following	 intranasal	 but	 not	 intracranial	 inoculation,	 suggesting	 that	 IFN	 produced	
during	 infection	 of	 olfactory	 bulb	 neurons	 induced	 IFIT2	 expression	 throughout	 the	
brain	(Fensterl	et	al.,	2012).	However,	when	inoculated	via	the	intranasal	route,	ns2H126R	
was	not	preferentially	 restricted	 relative	 to	A59	 (Figure	2.2),	 implying	 that	 the	cells	of	
the	 nasal	 epithelium	 and	 the	 olfactory	 neurons	were	 not	 better	 able	 to	 prevent	 viral	
invasion.	 Consistent	with	 these	 data,	we	 found	 no	 significant	 differences	 in	 the	 basal	
levels	of	Oas	mRNA	levels	among	RNA	samples	extracted	from	the	olfactory	bulbs	and	
from	other	regions	of	the	brain	(data	not	shown).	Interestingly,	however,	it	has	recently	
been	 reported	 that	 cultured	 granular	 neurons	 of	 the	 cerebellum	express	 higher	 basal	
levels	 of	 ISG	 mRNA,	 as	 compared	 with	 cortical	 neurons	 and	 are	 consequently	 more	
restrictive	of	infection	with	several	viruses	including	MHV-A59	(Cho,	2013).		
The	correlation	of	RNase	L	activation	with	high	basal	Oas	gene	expression	suggests	that	
production	of	2-5A	 is	 the	 limiting	step	 in	activation.	While	Oas	expression	 levels	were	
quite	variable	among	murine	cell	types,	we	found	similar	levels	of	RNase	L	expression	in	
murine	BMM	and	astrocytes	(Figure	3.3A&B),	cell	types	expressing	high	and	low	levels	
of	Oas	genes,	respectively.	Furthermore,	basal	levels	of	Rnasel	transcripts	and	proteins	
were	not	dependent	on	IFNAR	signaling	in	BMM	(Figure	3.5C).	However,	to	investigate	
whether	a	high	level	of	RNase	L	could	overcome	the	requirement	for	high	OAS	levels	to	
produce	 2-5A,	 we	 carried	 out	 infections	 in	 murine	 3T3/pLZ	 cells,	 which	 overexpress	
RNase	 L	 to	 a	 level	 about	 100	 fold	 greater	 than	 endogenous	 RNase	 L	 (A.	 Zhou	 et	 al.,	
1998).	RNase	L	was	not	activated	 in	 this	cell	 type	by	either	A59	or	ns2H126R,	 indicating	
that	OAS	activity	 is	 the	 limiting	step	 for	RNase	L	activation	as	extremely	high	 levels	of	
RNase	 L	 were	 not	 sufficient	 to	 overcome	 insufficient	 levels	 of	 Oas	 gene	 expression	
(Figure	3.3).	
	
We	 present	 further	 evidence	 that	 in	 myeloid	 cells,	 RNase	 L	 can	 be	 activated	 in	 the	
absence	 of	MDA5,	 the	 recognition	 receptor	 necessary	 for	 the	 induction	 of	 IFN	 during	
MHV	 infection	 (Roth-Cross,	 Bender,	 &	Weiss,	 2008),	 as	 long	 as	Oas	 gene	 expression	
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remains	at	a	minimum	threshold	 level	maintained	by	basal	 IFN	signaling.	The	 reduced	
levels	 of	Oas	 gene	 expression	 in	 BMM	derived	 from	Ifnar1-/-	mice	 or	 B6	mice	 treated	
with	 5	 µg/mL	 IFNAR1	 blocking	 antibody	 preclude	 the	 activation	 of	 RNase	 L	 during	
ns2H126R	 infection.	 These	 data	 suggest	 that	 the	 basal	 level	 of	Oas	 expressed	 in	 BMM	
derived	 from	WT	 B6	 or	Ifih1-/-	mice	 is	 adequate	 to	 produce	 enough	 2-5A	 to	 activate	
RNase	L	in	the	absence	of	virus-induced	IFN.		
	
Differences	in	anatomical	structure	and	cellular	composition	of	the	liver	and	brain	might	
account	for	the	differences	observed	with	MHV-A59	and	ns2H126R	infection.	The	liver	is	a	
detoxifying	organ	that	helps	filter	blood	from	numerous	pathogens	and	debris	through	
its	 vast	network	of	 small	blood	vessels	or	 sinusoids.	Ongoing	 immune	 responses	 from	
constant	antigen	exposure	may	induce	type	I	IFN	expression	and	maintain	higher	basal	
levels	of	ISG	expression	in	the	liver	than	in	the	brain	(Zhao,	2011;	Cho,	2013).	The	liver	
parenchyma	 is	 composed	 mainly	 of	 hepatocytes,	 while	 non-parenchymal	 KC,	 the	
resident	 macrophages	 of	 the	 liver,	 and	 liver	 sinusoidal	 endothelial	 cells	 (LSEC)	 are	
located	within	the	sinusoids	(Crispe,	2009).	LSEC	line	the	sinusoids	of	the	 liver	and	are	
some	 of	 the	 first	 cells	 to	 be	 exposed	 to	 pathogens	 entering	 the	 liver	 from	 the	
bloodstream.	We	have	proposed	that	KC	serve	as	a	gatekeeper	to	restrict	entrance	from	
the	sinusoids	into	the	liver	parenchyma	to	infect	hepatocytes	(Zhao,	2011;	Zhou,	2010;	
Cho,	 2013).	 We	 suggest	 that	 upon	 infection	 of	 KC,	 the	 IFN	 response,	 including	
importantly	the	OAS-RNase	L	pathway,	creates	an	antiviral	state	restricting	infection	and	
limiting	 spread	 of	 virus	 to	 the	 parenchymal	 hepatocytes,	 consequently	 preventing	
hepatitis.	This	hypothesis	 is	supported	by	the	following	observations.	Infection	of	mice	
with	CD11b+	cell	type	specific	ablation	of	type	I	interferon	receptor	expression	(Ifnar1-/-)	
demonstrated	 that	 IFN	 signaling	 in	 macrophages	 is	 crucial	 for	 control	 of	 hepatitis	
induced	 by	 MHV	 (Cervantes-Barragan	 et	 al.,	 2009)	 as	 well	 as	 by	 lymphocytic	
choriomeningitis	virus	(Lang	et	al.,	2010).	Expression	of	an	active	ns2	phosphodiesterase	
by	 A59	 facilitates	 viral	 replication	 in	 macrophages	 by	 antagonizing	 the	 OAS-RNase	 L	
pathway,	 thus	downregulating	 the	 IFN	 response;	 this	promotes	 replication	 in	 the	 liver	
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parenchyma,	 leading	 to	 hepatitis	 (Zhao	 et	 al.,	 2011b).	 Depletion	 of	 macrophages	
promotes	replication	of	ns2H126R	and	the	subsequent	development	of	liver	pathology	in	
B6	mice	(Zhao	et	al.,	2011b),	demonstrating	that	replication	in	KC	is	not	required	for	the	
induction	 of	 hepatitis,	 but	 rather	 that	 KC	 protect	 the	 host	 from	 viral	 infection.	 In	
addition,	 KC	 have	 highest	 basal	 and	 IFN-induced	 levels	 of	 OAS	 among	 liver	 cell	 types	
(Asada-Kubota	et	al.,	1998).	In	fact,	LSEC	are	able	to	restrict	the	ns2H126R,	activate	RNase	
L,	and	have	high	basal	Oas	mRNA	expression	levels.		
	
In	 comparison	 to	 the	 liver,	 the	 dichotomous	 needs	 for	 pathogen	 elimination	 and	
protection	 from	 cellular	 damage	 make	 the	 mammalian	 CNS	 a	 partially	 protected	
environmental	niche	that	is	a	prime	target	for	viral	infections.	The	concept	of	the	CNS	as	
an	immune-privileged	organ	has	many	to	believe	that	it	is	not	an	active	immunological	
organ,	 guarded	 from	 its	 surroundings	 by	 the	 blood-brain	 barrier	 (BBB).	 However,	 the	
CNS	 is	a	highly	 immunologically	active	organ,	with	complex	 immune	 responses	mostly	
based	 on	 innate	 immune	 processes.	 In	 cases	 of	 infections,	 traumas,	 and	 pathological	
conditions,	 the	 CNS	 encounters	 many	 viral	 PAMPS	 that	 can	 activate	 PRRs	 to	 elicit	
antiviral	mechanisms.	The	role	for	these	receptors	in	the	CNS	has	been	mostly	studied	in	
microglia,	but	astrocytes,	oligodendrocytes,	endothelial	cells,	and	even	neurons	express	
functional	 levels	 of	 some	of	 these	 receptors	 (Hanamsagar	 et	al.,	 2012).	 	Microglia	 are	
distinct	from	the	monocyte	lineage	of	cells	and	other	tissue-specific	macrophages	such	
as	KC	 in	 the	 liver,	 for	which	maintenance	 is	dependent	upon	 the	 recruitment	of	bone	
marrow-derived	cells	(BMDCs)	from	the	circulation	(Klein	et	al.,	2007).	In	the	CNS,	BMDC	
recruitment	 does	 not	 occur	 during	 normal	 physiology	 (Lampron	et	al.,	 2012).	When	 it	
comes	 to	 its	 defense,	 CNS	 integrity	 is	 guarded	 exclusively	 through	 an	 innate	 immune	
system	 with	 an	 adaptive	 immunity	 only	 present	 in	 specific	 conditions	 (Rivest,	 2009).	
These	features	make	the	CNS	immune	response	much	different	from	the	liver	and	other	
peripheral	organs	upon	infections.	
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Therefore,	this	means	a	complex	immune	reaction	is	engaged	in	the	CNS	in	response	to	
mechanical	or	ischemic	traumas,	the	accumulation	of	toxic	proteins,	or	bacterial	or	viral	
infections.	A59	infects	all	major	CNS	cell	types	in	vivo	(Bender	et	al.,	2010;	Miura	et	al.,	
2008)	as	well	as	in	vitro	(Figure	2.5A-E).	Intracranial	infection	provides	immediate	access	
to	 all	 cell	 types.	 Numerous	 cell	 types	 act	 to	 maintain	 CNS	 integrity	 and	 function,	
separated	into	three	main	groups:	neurons,	the	glia,	and	endothelial	cells.	Neurons,	glial	
cells,	 and	 endothelial	 cells	 exist	 in	 close	 proximity	 of	 each	 other,	 forming	 the	
neurovascular	unit	(NVU),	a	coherent	view	of	the	CNS	as	a	whole	instead	of	a	blend	of	
compartmentalized	cell	types	(Zlokovic,	2008).		
	
Neurons,	the	most	abundant	cell	type	in	the	murine	brain,	generally	express	low	levels	
of	 ISG	 mRNA	 and	 minimal	 basal	 levels	 of	 Oas	 mRNA,	 allowing	 for	 robust	 virus	
replication.	 Astrocytes	 and	 oligodendrocytes	 are	 similarly	 susceptible	 to	 infection.	
However,	 tissue-resident	 macrophages	 called	 microglia,	 much	 like	 KC	 in	 the	 liver	 or	
histiocytes	in	connective	tissues,	are	the	only	cells	in	the	CNS	that	are	of	hematopoietic	
origin	 (Soulet	 and	 Rivest,	 2008b).	 Fate-mapping	 analysis	 has	 demonstrated	 that	
hematopoietic	 precursors	 from	 the	 yolk	 sac	 populate	 the	 CNS	 before	 the	 eighth	
embryonic	 day	 in	mice	 (Ginhoux	 et	al.,	 2010).	 Once	 present,	microglia	 are	 capable	 of	
self-renewal	 and	 do	 not	 require	 replenishment	 from	 circulating	monocytic	 precursors	
(Ajami	et	al.,	2007).	Microglia	also	restrict	ns2H126R	 replication	(Figure	2.5D),	albeit	 less	
so	 than	 BMMs	 (K.	 M.	 Rose,	 Elliott,	 Martinez-Sobrido,	 Garcia-Sastre,	 &	 Weiss,	 2010;	
Kristine	M.	 	Rose	&	Weiss,	2009;	Roth-Cross,	Martinez-Sobrido,	Scott,	Garcia-Sastre,	&	
Weiss,	2007)	and	would	be	expected	to	limit	replication	in	the	brain	in	vivo.	We	suggest	
that	microglia	are	not	able	 to	 significantly	 restrict	ns2H126R	 in	 the	CNS	 in	part	because	
they	 represent	 a	 minority	 of	 infected	 cells	 (Phillips,	 Chua,	 Rall,	 &	 Weiss,	 2002).	 In	
addition,	by	the	time	microglia	and	infiltrating	macrophages	have	secreted	IFN,	which	is	
late	during	A59	infection	(K.	M.	Rose	et	al.,	2010;	Kristine	M.		Rose	&	Weiss,	2009;	Roth-
Cross	et	al.,	2007),	it	may	be	too	late	to	induce	OAS-RNase	L	in	other	parenchymal	cell	
types	 already	 infected	 by	 virus.	 Furthermore,	 our	 in	 vitro	 data	 suggest	 that	 IFN	
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pretreatment	 of	 neurons,	 astrocytes,	 and	 oligodendrocytes	 also	 fails	 to	 promote	 an	
effective	RNase	L	response	in	MHV	infected	cells.	In	this	case,	IFN	pretreatment	leads	to	
restriction	of	virus	replication	for	both	viruses	and	not	just	preferentially	with	ns2H126R.	
This	suggests	that	in	different	cell	types,	different	pathways	and	ISGs	are	important	for	
restriction.	Our	data	however	do	not	rule	out	the	possibility	that	a	combination	of	IFN	
exposure	 and	 infection	 may	 trigger	 RNase	 L	 activity	 in	 the	 CNS	 in	 vivo.	 Indeed,	
expression	of	Oas	was	reported	for	neurons	in	brains	that	had	been	injected	with	IFNα	
(Asada-Kubota	 et	 al.,	 1997).	 Consistent	 with	 our	 results,	 an	 attenuated	 MHV-JHM	
isolate,	with	 tropism	 restricted	 to	 oligodendrocytes,	 replicated	 to	 similar	 titers	 in	 the	
CNS	 of	 Rnasel-/-	 and	 B6	 mice;	 however,	 increased	 foci	 of	 infected	 microglia	 were	
observed	 in	 the	gray	matter	 in	Rnasel-/-	mice,	 implying	OAS-RNase	L	did	provide	some	
protection	against	viral	infection	of	microglia	in	that	model	(Ireland	et	al.,	2009).		
Indeed,	 responses	 in	 this	 compartment	 must	 be	 tightly	 regulates	 as	 the	 CNS	 is	
composed	 predominantly	 of	 non-renewable	 cells	 such	 as	 neurons.	 Thus,	 unregulated	
immune	responses	could	be	irreparably	destructive	to	the	CNS.	High	levels	of	IFNα	can	
be	 pathogenic	 in	 the	 CNS,	 as	 illustrated	 by	 individuals	 with	 Aicardi-Goutières,	 who	
produce	 high	 levels	 of	 IFNα	 in	 their	 cerebral	 spinal	 fluid	 and	 exhibit	 symptoms	 of	
chronic	 encephalitis	 (Paul	 et	 al.,	 2007;	 Stephenson,	 2008).	 Unregulated	 RNase	 L	
mediated	degradation	has	been	reported	to	promote	apoptosis	potentially	damaging	to	
non-renewable	cells	(Castelli	et	al.,	1998).	The	failure	to	respond	to	ns2H126R	infection	by	
activation	 of	 the	 OAS-RNase	 L	 pathway	 in	 neurons,	 astrocytes,	 and	 oligodendrocytes	
may	reflect	the	relatively	low	basal	levels	of	ISG	expression	that	may	limit	the	damaging	
effects	of	excessive	IFN	signaling	(Zhao,	2011;	Cho,	2013).	Excessive	IFN	has	pathological	
effects,	contributing	to	several	autoimmune	diseases	and	promoting	cancer	(de	Visser,	
2006;	Gough,	2012;	Trinchieri,	2010).			
	
Given	 the	 protective	 and	 harmful	 roles	 of	 IFN,	 it	 is	 is	 vital	 for	 control	 of	 early	 MHV	
infection	in	vivo	(Cervantes-Barragan	et	al.,	2007;	Ireland,	Stohlman,	Hinton,	Atkinson,	&	
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Bergmann,	2008;	Roth-Cross	et	al.,	2008).	However,	MHV	and	other	coronaviruses,	such	
as	 SARS-CoV	and	MERS-CoV	are	poor	 inducers	of	 IFN	as	 they	 actively	 inhibit	 a	 robust	
type	 I	 IFN	 response	 in	 infected	 cells	 (Roth-Cross,	 2007;	 Spiegel,	 2005;	Versteeg,	2007;	
Chan,	2013;	Kindler,	2013;	Zielecki,	2013).	In	the	case	of	MHV,	IFN	is	not	detected	during	
infection	of	 cell	 lines	 nor	 in	 several	 types	 of	 primary	 cells	 in	 vitro,	 including	 the	main	
types	of	cells	infected	in	the	brain	(neurons,	astrocytes,	and	oligodendrocytes)	and	liver	
(hepatocytes)	parenchymal	 cells.	However,	MHV	does	 induce	 IFN	 in	macrophages	and	
microglia	 (Roth-Cross	 et	 al.,	 2008)	 as	well	 as	 pDCs	 in	 vivo	 (Cervantes-Barragan,	 2012)	
and	in	myeloid	cells	in	vitro	(Roth-Cross	et	al.,	2008).	These	are	the	same	types	of	cells	
expressing	 high	 levels	 of	 basal	Oas	 genes	 and	which	 activate	 RNase	 L	 in	 response	 to	
ns2H126R,	 probably	 as	 a	 consequence	 of	 the	 high	 expression	 levels	 of	 ISGs	 including	
MDA5	 and	 the	 transcription	 factors	 necessary	 for	 IFN	 induction	 (Chen,	 2013;	 Zhao,	
2011).	Thus,	 in	vivo,	 low	Oas	gene	expressing	cells	may	be	induced	by	paracrine	IFN	to	
increase	OAS	levels	enabling	viral	activation	of	RNase	L.	Indeed,	in	previous	experiments	
reported	 by	 our	 lab,	 pretreatment	 of	 astrocyte	 or	 neurons	with	 IFN	 did	 increase	 the	
levels	of	Oas	gene	expression	(Zhao,	2013).	However,	IFN	pretreatment	also	resulted	in	
decreased	 titers	of	both	A59	and	ns2H126R	and	 the	absence	of	activation	of	RNase	L	 in	
those	experiments	was	suggested	to	be	a	consequence	of	 reduced	ability	of	both	A59	
and	ns2H126R	to	 replicate	and	produce	dsRNA	 following	 IFN	pretreatment	 (Zhao,	2013).	
Data	here	suggest	IFN	treatment	induces	many	antiviral	ISGs	some	of	which	inhibit	viral	
replication	 without	 the	 activation	 of	 RNase	 L.	 Taken	 together	 our	 data	 indicate	 high	
basal	Oas	levels	are	both	necessary	and	sufficient	for	the	activation	of	RNase	L	by	MHV	
lacking	a	functional	viral	PDE.	
	
Type	I	IFNs	are	produced	constitutively	in	low	quantities–barely	detectable	at	the	mRNA	
and	 protein	 levels	 in	 some	 cell	 types,	 such	 as	 BMM	 cultures	 (Figure	 3.5E,	 data	 not	
shown)	 and	 undetectable	 in	most	 other	 cell	 types	we	 have	 tested	 (data	 not	 shown).	
However,	this	low	level	of	constitutive	IFN	is	believed	to	have	many	important	effects	on	
the	host.	In	a	healthy	organism,	ever-present	low	amounts	of	IFNβ	maintain	appropriate	
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expression	of	 IFN-inducible	signaling	 intermediaries,	 including	 the	transcription	 factors	
STAT1,	STAT2,	IRF5,	IRF7,	and	IRF9.	Most	cell	types	are	competent	to	mount	type	I	IFN-
dependent	responses.	 Immune	cells	can	respond	rapidly	to	 low	 levels	of	type	 I	 IFNs,	a	
capacity	 maintained	 under	 homeostatic	 conditions	 by	 an	 positive	 autocrine	 loop	
whereby	small	amounts	of	 IFNβ	maintain	high	basal	expression	 levels	of	Stat1	and	Irf9	
which	 are	 themselves	 ISGs	 (Gough,	 2012).	 Basal	 IFNβ	 expression	 and	 attendant	 tonic	
IFNAR	 signaling	 equips	 immune	 cells	 to	 rapidly	 mobilize	 effective	 antimicrobial	
programs.	Appropriate	 expression	 allows	 a	balance	between	 STAT1	or	 ISGF3	 signaling	
and	 signaling	 through	 other	 STAT	 proteins	 (e.g.,	 STAT4).	 Diminished	 constitutive	 IFNβ	
secretion	results	in	decreased	expression	of	ISGF3	subunit	proteins,	altering	the	balance	
of	 signaling	 (e.g.,	 between	 ISGF3	 and	 STAT4)	 and	 culminating	 in	 susceptibility	 to	
infection	 and	 cancer,	 inefficient	 hematopoietic	 stem	 cell	 (HSC)	 mobilization,	 and	
increased	 bone	 resorption.	 Constitutive	 IFN	 signaling	 promotes	 rapid	 and	 efficient	
responses	to	microbial	invasion	as	evidenced	by	the	extreme	sensitivity	of	Ifnar1-/-	mice	
to	many	viruses,	including	MHV	(de	Visser,	Eichten,	&	Coussens,	2006;	Gough,	Messina,	
Clarke,	Johnstone,	&	Levy,	2012;	Trinchieri,	2010).	Recent	work	suggests	that	basal	IFNβ	
production	under	homeostatic	conditions	is	driven	in	part	by	the	commensal	microbial	
flora,	which	thus	can	systemically	calibrate	type	I	IFN	responses	(Abt,	2012;	Ganal,	2012;	
Kawashima,	2013).	
Somewhat	paradoxically,	loss	of	constitutive	IFNβ	or	loss	of	IFN	responsiveness	(e.g.,	as	
observed	 in	 Ifnar1-/-animals)	 attenuates	 cellular	 responses	 not	 only	 to	 type	 I	 IFNs	 but	
also	 to	 unrelated	 cytokines,	 such	 as	 IFNγ	 and	 IL-6	 (Takaoka	 et	al.,	 2000;	Mitani	 et	al.,	
2001;	Der	et	al.,	1998;	Weihua	et	al.,	2000).	While	the	transcriptional	regulation	of	IFNβ	
mRNA	 expression	 in	 the	 context	 of	 viral	 infection	 is	 extensively	 characterized,	 less	 is	
known	 regarding	 the	 transcriptional	 regulation	 of	 constitutive	 IFNβ.	 For	 virus-induced	
IFNβ	expression,	IRF3	and	IRF7	appear	to	be	essential	(Hata	et	al.,	2001	and	Sato	et	al.,	
2000).	The	binding	of	each	of	these	components	in	the	correct	orientation	and	location	
results	 in	 activation	 of	 the	 IFNβ	 promoter	 in	 response	 to	 viral	 infection.	 The	 most	
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notable	distinction	from	acutely	induced	IFN	expression	is	a	switch	from	dependency	on	
IRF3	 and	 IRF7	 to	 c-Jun	 and	 NF-κB	 components.	 Threshold	 expression	 of	 IFNβ	 in	
unstimulated	 cells	 is	 governed	 by	 IRF2	 and	 p50	 homodimers,	 both	 of	 which	 are	
constitutively	expressed	and	bind	the	IFNβ	promoter	as	repressors	(Gough,	2012;	Cheng	
et	al.,	 2011,	 Senger	 et	al.,	 2000,	 Thanos	 and	Maniatis,	 1995	and	Harada	 et	al.,	 1989).	
IRF2-deficient	cells	have	heightened	expression	of	IFNα	and	IFNβ	and	IFN	target	genes.	
Irf2-/-	mice	 develop	 a	 psoriasis-like	 skin	 disease	 that	 is	 ameliorated	 by	 removing	 IFN	
signaling,	 such	 as	 ablation	 of	 Ifnar1	 (Arakura	 et	al.,	 2007	and	Honda	 et	al.,	 2003).	
Animals	 with	 p50	 deficiency	 are	 developmentally	 normal	 with	 no	 signs	 of	 the	 skin	
disease	 caused	 by	 IRF2	 loss,	 suggesting	 a	 lesser	 role	 for	 p50	 as	 a	 repressor	 of	
constitutive	IFNβ	(Sha	et	al.,	1995).	These	reports	document	that	the	IFNβ	promoter	 is	
occupied	 by	 both	 transcription	 activators	 (c-Jun	 and	 RelA)	 and	 suppressors	 (IRF2	 and	
p50	homodimers),	 the	 balance	of	which	maintain	 tight	 control	 of	 constitutive	 IFNβ	 in	
the	 absence	 of	 overt	 stimulation.	 IRF2	might	 play	 a	 significant	 role	 in	 preventing	 the	
detrimental	 cellular	 effects	 in	 the	 brain	 during	 infection.	 Indeed,	 levels	 of	 Irf2	mRNA	
expression	 is	 significantly	 higher	 in	 astrocytes	 than	 in	 BMM.	 This	 suggests	 that	
astrocytes	 are	 transcriptionally	 repressed	 and	 do	 not	 respond	 to	 IFN	 as	 efficiently	 as	
BMM	respond.		
The	 aforementioned	methods	 are	 not	 the	 only	mechanisms	 that	 suppress	 type	 I	 IFN-
mediated	 responses,	 including	 downregulation	 of	 cell	 surface	 IFNAR	 expression.	
Internalization	 of	 IFNAR	 is	 induced	 by	 various	 heterologous	 pathways	 to	 limit	 cellular	
IFN	 responsiveness	 (Fuchs,	 2013;	 de	 Weerd,	 2012).	 Viruses	 can	 induce	 IFNAR	
degradation	to	evade	type	 I	 IFN-mediated	antiviral	 responses	 (Fuchs,	2013;	Liu,	2009).	
Encephalitic	 flaviviruses,	 tick-borne	 encephalitis	 virus,	 and	West	 Nile	 virus	 antagonize	
IFN	 signaling	 by	 downregulating	 IFNAR1	 surface	 expression	 thus	 reducing	 IFNβ-
stimulated	antiviral	gene	 induction	and	compromising	host	control	of	 infection	(Lubick	
et	al.,	2015).	Interestingly,	in	a	reovirus	model	of	myocarditis,	surface	expression	levels	
of	IFNAR	as	well	as	basal	ISG	levels	were	higher	in	cardiac	fibroblasts	as	compared	with	
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cardiac	myocytes.	It	was	suggested	that	upon	exposure	to	IFN,	cardiac	fibroblasts	could	
quickly	develop	an	antiviral	state	and	thereby	avoid	serving	as	a	site	of	replication	and	
spread	 to	 the	 non-renewable	 cardiac	 myocytes	 (Zurney,	 Howard,	 &	 Sherry,	 2007).	
Similarly,	 our	 data	 suggest	 that	 astrocytes	 have	 relatively	 lower	 IFNAR1	 surface	
expression	 compared	 to	 microglia	 in	 the	 brain	 or	 BMM	 (Figure	 3.5G),	 which	 could	
contribute	to	the	lower	level	of	basal	ISG	expression.	MHV	might	induce	the	degradation	
of	the	IFNAR	receptor	on	the	surface	of	non-myeloid	cells	to	down	play	the	pathological	
effects	of	IFN	signaling	in	the	CNS.		
	
In	fact,	recent	work	has	revealed	that	even	in	populations	of	nearly	identical	cells,	not	all	
cells	 that	are	 infected	by	a	virus	or	exposed	to	microbial	products	produce	type	 I	 IFNs	
and	 express	 ISGs.	 The	 stochastic	 nature	 of	 ISG	 expression	 seems	 to	 be	 related	 to	
bimodal	induction	of	STAT2	and	IRF7,	which	can	drive	high	amounts	of	ISG	transcription	
in	a	particular	subset	of	cells,	whereas	other	cells	express	much	 lower	amounts	of	 ISG	
transcripts.	 The	 biological	 purpose	 of	 stochasticity	 is	 unclear,	 but	 some	 evidence	
suggests	that	it	generates	cells	that	are	'mass	IFN	producers'	(Hwang,	2013;	Zhao	et	al.,	
2012;	 Shalek,	 2013).	 These	 mass	 IFN	 producers	 help	 combat	 infection	 but	 might	 be	
more	 susceptible	 to	 cell	 death,	 while	 'low	 IFN	 producers'	 are	 preserved	 in	 order	 to	
maintain	the	viability	of	tissues.	Microglia	might	be	mass	IFN	produces	and	responders	
that	are	easily	sacrificed	to	maintain	and	ensure	CNS	integrity.	
		
Futhermore,	 in	macrophages,	 suppressor	 of	 cytokine	 signaling	 3	 (SOCS3),	 a	 gene	 that	
encodes	a	member	of	the	STAT-induced	STAT	inhibitor	(SSI),	which	is	cytokine-inducible	
negative	regulators	of	cytokine	signaling.	SOCS3	is	not	as	highly	expressed	at	the	mRNA	
level	as	compared	to	non-myeloid	cells.	Type	I	IFN	induces	SOCS3	as	part	of	a	negative	
feedback	loop	to	limit	the	extent	and	duration	of	type	I	IFN	response	(Yoshimura,	2007;	
Sarasin-Filipowicz,	2009).	SOCS	proteins	compete	with	STATs	 for	binding	to	 IFNAR	and	
suppress	 JAK	 activity,	 whereas	 USP18	 displaces	 JAK1	 from	 IFNAR2.	 These	 inhibitory	
proteins	 are	 also	 induced	 by	 various	 cytokines	 that	 activate	 JAK–STAT	 signaling.	
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Potentially,	 non-myeloid	 cells	have	 less	 SOCS3	as	an	attempt	 to	 spare	 themselves	 the	
negative	 effects	 of	 rampant	 IFN	 signaling.	 Conversely,	 MHV	 might	 use	 this	 negative	
regulator	to	escape	from	type	I	IFN-mediated	antimicrobial	action.		
	
Additionally,	 a	 recent	 report	 identified	 DNA	 regulatory	 elements	 for	 the	 transcription	
factor	forkhead	box	protein	O3	(FOXO3)	in	several	ISG	promoters,	including	IRF7.	FOXO3	
proposed	functions	are	to	repress	basal	type	I	IFN	responses	and	shut	down	the	type	I	
IFN	response	during	the	resolution	phase	of	an	infection	(Litvak,	2012).	Relatively	little	is	
known	 about	 the	 repression	 of	 ISG	 expression,	 and	 the	 characterization	 of	 additional	
repressors	represents	an	important	area	for	future	study,	especially	for	cell	types	of	the	
brain	during	viral	infection.		
	
In	addition	to	a	cell	limiting	excessive	IFN	signaling,	RNase	L	must	be	managed	in	a	way	
that	 will	 not	 be	 detrimental	 to	 the	 host.	 RNA	 cleavage	 products	 stimulate	
inflammasome	 activation	 by	 binding	 to	 DExD/H	 helicase,	 DHX33	 (Chakrabarti,	 2015).	
Activation	of	RNase	L	induces	apoptosis	involving	activity	of	caspase	3	(Li,	2004)	in	some	
cell	types,	which	correlated	with	basal	levels	of	OAS	and	RNase	L	(Banerjee,	2014).	Also,	
activation	 of	 RNase	 L	 induces	 autophagy	 involving	 the	 activities	 of	 JNK	 and	 PKR	
(Siddiqui,	 2012).	Phosphorylation	of	Bcl2	by	 JNK	disrupts	 complexes	with	Beclin-1	and	
promotes	 complex	 formation	 with	 Vps34,	 which	 is	 required	 for	 autophagosome	
formation.	RNase	L-cleaved	RNAs	regulate	the	switch	from	autophagy	to	apoptosis	that	
can	determine	 fate	of	cells	during	viral	 infections.	The	role	of	RNase	L	 in	 the	crosstalk	
between	these	pathways	is	still	being	explored	(Siddiqui,	2015).	
	
One	possible	explanation	for	the	lack	of	activation	of	the	OAS-RNase	L	pathway	in	non-
myeloid	 cells	 despite	 the	 induction	 of	 other	 antiviral	 effectors	 is	 the	 requirement	 for	
viral	dsRNA	to	be	accessible	to	induce	the	synthesis	of	2-5A	by	OAS.	Indeed,	the	lack	of	
induction	of	type	I	IFN	response	in	non-myeloid	primary	cell	types	(Figure	2.7B)	as	well	
as	in	several	transformed	cell	lines	during	MHV	infection	provide	further	evidence	that	
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viral	RNA	may	not	be	accessible	for	detection	by	MDA5	in	non-myeloid	cells	(Roth-Cross	
et	al.,	2007;	Versteeg,	Bredenbeek,	van	den	Worm,	&	Spaan,	2007;	H.	Zhou	&	Perlman,	
2007).	 It	 has	 been	 speculated	 that	 MHV	 (Versteeg	 et	 al.,	 2007;	 H.	 Zhou	 &	 Perlman,	
2007),	 as	 well	 as	 other	 viruses	 such	 as	 tick-born	 encephalitis	 virus	 (Overby,	 Popov,	
Niedrig,	 &	 Weber,	 2010),	 induces	 a	 rearrangement	 of	 intracellular	 membranes	 that	
could	potentially	create	a	compartment	that	would	protect	viral	dsRNA	from	detection	
by	 cytoplasmic	 sensors	 (Hagemeijer,	 Vonk,	 Monastyrska,	 Rottier,	 &	 de	 Haan,	 2012;	
Knoops	et	al.,	2010;	Prentice,	McAuliffe,	Lu,	Subbarao,	&	Denison,	2004;	van	den	Worm	
et	al.,	2011;	van	Hemert	et	al.,	2008).	However,	to	our	knowledge	no	studies	of	MHV-
induced	membrane	rearrangement	or	 localization	of	viral	 transcription	complexes	and	
dsRNA	 have	 been	 carried	 out	 in	 myeloid	 cells.	 Future	 studies	 include	 comparing	 the	
localization	 of	 transcriptional	 complexes	 and	 viral	 dsRNA	 between	 macrophages	 and	
other	cell	types.		
	
It	is	possible	that	the	endothelial	cells	that	line	the	blood	vessels	and/or	the	ependymal	
cells	that	line	the	ventricles	of	the	brain	may	express	relatively	high	levels	of	interferon-
stimulated	genes,	including	Oas,	and	thus	provide	a	barrier	to	viral	entry	into	the	brain	
parenchyma	 that	 is	 bypassed	 by	 intracranial	 and	 intranasal	 inoculation.	 Indeed,	while	
MHV	does	not	spread	into	the	brain	after	peripheral	inoculation	in	B6	mice,	intrahepatic	
inoculation	readily	produces	encephalitis	in	mice	impaired	in	type	I	interferon	signaling	
(either	 Ifnar1-/-or	 Ifih1-/-	 mice;	 unpublished	 data).	 Endothelial	 cells	 are	mediators	 and	
sensors	of	peripheral	 immune	responses	 that	connect	and	 inform	the	CNS	of	 immune	
processes.	Endothelial	cells	are	in	constant	contact	and	crosstalk	with	blood	circulation	
and	 under	 continuous	 challenges.	 These	 cells	 are	 the	 first	 line	 defenders	 against	 CNS	
attack	 and	 demonstrate	 an	 active	 role	 in	 CNS	 innate	 immunity	 (Danese	 et	al.,	 2007).	
Under	 physiological	 conditions,	 endothelial	 cells	 are	 immunologically	 quiescent,	 but	
during	an	infection,	bioactive	molecules	modulate	BBB	integrity	(Laflamme	et	al.,	1999;	
Schiltz	 and	 Sawchenko,	 2002)	 to	 facilitate	 immune	 cell	 migration	 into	 the	 brain	
parenchyma.	Furthermore,	ependymal	cells	have	been	shown	to	express	higher	levels	of	
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Oas	mRNA	than	other	CNS	cells	 in	vivo	 (Asada-Kubota	et	al.,	1997).	Future	studies	will	
be	directed	at	investigating	the	possibility	that	one	or	both	of	these	cells	types	may	play	
a	gatekeeping	role	similar	to	the	function	proposed	for	KC	in	the	liver	and	thus	prevent	
the	spread	of	peripheral	viral	infections	into	the	brain.	
	
In	 conclusion,	 early	 protection	 of	 the	 host	 against	 viral	 infections	 relies	 on	 the	 rapid	
detection	 of	 the	 pathogen	 and	 optimal	 activation	 of	 the	 type	 I	 IFN	 response.	 A	 cell	
encountering	type	I	IFNs	in	the	absence	of	other	cues	will	activate	the	classical	antiviral	
state	 by	 upregulating	 expression	 of	 interferon-inducible	 genes.	 These	 genes	 include	
nucleic	acid	sensors	like	RIG-I	and	MDA5;	increased	abundance	of	these	sensors	would	
make	cells	surrounding	an	 infected	cell	more	sensitive	 to	detection	of	virus.	However,	
the	 induction	 of	 IFN	 and	 subsequent	 upregulation	 of	 ISGs	 through	 RIG-1	 and	 MDA5	
might	be	too	slowly	induced	in	infected	cell	types	and	whole	organs.	Data	presented	as	
part	 of	 this	 thesis	 underscores	 the	potential	 for	OAS	proteins	 to	 serve	 as	nucleic	 acid	
sensors	that	activate	an	RNA	decay	pathway	and	apoptosis	though	the	use	of	RNase	L.	
This	 might	 allow	 the	 quick	 disposal	 of	 infected	 cells	 before	 the	 IFN	 response	 and	
signaling	cascade	have	begun.	This	process	could	spare	neighboring	infected	cells	from	
infection.		
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V	
CHAPTER	FIVE	
EXPERIMENTAL	FRAMEWORK	AND	NOTATION	
	
Ethics	statement.	This	study	was	in	strict	accordance	with	federal	regulations	set	forth	
in	the	Animal	Welfare	Act	(AWA),	recommendations	in	the	Guide	for	the	Care	and	Use	
of	 Laboratory	 Animals	 of	 the	 National	 Institutes	 of	 Health,	 and	 the	 guidelines	 of	 the	
University	of	Pennsylvania	Institutional	Animal	Use	and	Care	Committee.	The	protocols	
were	approved	by	the	Institutional	Animal	Care	and	Use	Committee	at	the	University	of	
Pennsylvania.	
	
Viruses,	 cell	 lines,	 and	 mice.	 Murine	 L2	 fibroblasts	 were	 maintained	 in	 Dulbecco’s	
modified	 Eagle’s	medium	 (DMEM)	 supplemented	with	 10%	 fetal	 bovine	 serum	 (FBS),	
HEPES	 (10	mM),	 and	1%	penicillin-streptomycin.	Plaque	assays	were	performed	on	 L2	
cells	 as	 described	 previously	 (Gombold,	 Hingley,	 &	 Weiss,	 1993).	 Murine	 3T3/pLZ	
fibroblasts	 were	 grown	 in	 DMEM	 containing	 10%	 FBS	 supplemented	 with	 G418	 (350	
µg/mL)	and	1%	penicillin-streptomycin	(Zhou	et	al.,	1998;	Zhou,	Paranjape	et	al.	1998).	
The	 recombinant	 coronaviruses	 inf-MHV-A59	 (wild	 type	A59,	 referred	 to	as	A59	here)	
and	 inf-ns2-H126R	(referred	to	as	ns2H126R	here)	were	obtained	from	Dr.	Stuart	Siddell	
(University	 of	 Bristol,	 Bristol,	 United	 Kingdom)	 and	 have	 been	 described	 previously	
(Roth-Cross	 et	 al.,	 2009;	 Zhao,	 Rose,	 Elliott,	 Van	 Rooijen,	 &	Weiss,	 2011;	 Roth-Cross,	
Stokes	 et	 al.	 2009,	 Zhao,	 Rose	 et	 al.	 2011).	 Newcastle	 disease	 virus	 expressing	 green	
fluorescent	 protein	 (NDV-GFP)	 (Park	 et	 al.,	 2003;	 Roth-Cross,	 Bender,	 &	Weiss,	 2008;	
Zhao	et	al.,	2013;	Park,	Shaw	et	al.	2003,	Roth-Cross,	Bender	et	al.	2008,	Zhao,	Birdwell	
et	al.	2013)	was	obtained	from	Dr.	Luis	Martinez-Sobrido	(University	of	Rochester	School	
of	 Medicine).	 C57BL/6	 (B6)	 mice	 were	 purchased	 from	 the	 National	 Cancer	 Institute	
(Frederick,	MD).	Rnasel-/-	mice	(bred	for	10	generations	to	obtain	a	B6	background)	were	
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described	 previously	 (Zhou	 et	 al.,	 1997;	 Zhou,	 Paranjape	 et	 al.	 1997).	 Ifih1-/-	 Gitlin,	
Barchet	et	al.	2006)	and	Ifnar1-/-	(Pinto	et	al.,	2011;	Pinto,	Daffis	et	al.	2011)	mice,	both	
with	 B6	 background,	 were	 obtained	 from	 Dr.	 Michael	 S.	 Diamond	 (Washington	
University	in	St.	Louis,	St.	Louis,	MO).	Both	strains	were	further	bred	and	maintained	in	
the	animal	facility	at	the	University	of	Pennsylvania.		
	
Quantitative	 reverse	 transcribed	 PCR.	 RNA	 was	 isolated	 with	 an	 RNeasy	 minikit	
(Qiagen,	Valencia,	CA).	Quantitative	real-time	reverse	transcriptase-PCR	(qRT-PCR)	was	
performed	 as	 described	 previously	 (Zhao,	 Rose,	 Elliott,	 Van	 Rooijen,	 &	Weiss,	 2011).	
Briefly,	200	ng	(cells)	or	350	ng	(tissue)	of	total	RNA	was	reverse	transcribed	into	cDNA	
using	reverse	transcriptase	(Superscript	III;	Invitrogen)	in	a	total	volume	of	20	μL.	Then,	
2	μL	of	cDNA	was	combined	with	12.5	μL	of	iQ5	SYBR	green	mix	(Bio-Rad,	Hercules,	CA),	
6.5	μL	diethyl	pyrocarbonate	 (DEPC)-treated	water,	and	4	μL	primer	mix	 (5	μM	each).	
DNA	was	amplified	using	an	iQ5	iCycler	(Bio-Rad),	and	cycle	threshold	(CT)	values	were	
recorded.	 Expression	 levels	of	mRNA	were	quantified	as	ΔCT	 values	 relative	 to	β-actin	
mRNA	with	the	equation:	2-ΔCT,	where	∆CT	=	(CT,	Target	Gene	-	CT,	β-actin).	Quantitative	RT-PCR	
primer	sequences	are	available	upon	request.				
	
Primary	 cell	 cultures.	 (i)	 Bone	marrow-derived	macrophages	 (BMM)	 were	 generated	
from	 the	 hind	 limbs	 of	 B6	 (WT),	 Ifih1-/-,	 or	 Ifnar1-/-	 mice	 as	 described	 previously	
(Caamano,	 Alexander,	 Craig,	 Bravo,	 &	 Hunter,	 1999;	 Casson	 et	 al.,	 2013;	 Zhao	 et	 al.,	
2012{Casson,	2013	#47)(Caamano,	Alexander	et	al.	1999,	Zhao,	Jha	et	al.	2012	{Casson,	
2013	#47},	Casson,	Copenhaver	et	al.	2013)	and	cultured	in	DMEM	supplemented	with	
10%	FBS	and	30%	L929	 cell-conditioned	medium	 for	 6	days	before	 infection.	 Cultures	
were	routinely	≥99%	pure	as	assessed	by	positive	staining	for	expression	of	CD11b	and	
negative	 staining	 for	 expression	 of	 CD11c.	 (ii)	 Bone	 marrow-derived	 dendritic	 cells	
(BMDC)	were	generated	from	the	hind	 limbs	of	WT	mice	as	described	by	{Inaba,	1992	
#46;Copenhaver,	2014	#108}	and	cultured	in	RPMI	1640	(Sigma-Aldrich)	supplemented	
with	 10%	 FBS,	 2	 mM	 L-glutamine,	 1%	 penicillin-streptomycin,	 50	 µM	 β-
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mercaptoethanol,	and	20	ng/mL	of	GM-CSF	(Peprotech).	The	cells	were	fed	on	day	3,	6,	
and	8	with	fresh	media	and	supplements.	On	day	10,	cells	were	harvested	and	replated	
at	200,000	cells/well	using	growth	media	with	5	ng/mL	GM-CSF	on	24-well	non-tissue	
culture	treated	plates	and	used	for	infections.	Cells	were	routinely	>95%	CD11c+	and	80	
to	90%	 immature	 (MHCIIlo).	 (iii)	Hippocampal	neurons	were	prepared	 from	embryonic	
day	 15.5	 (E15	 to	 E16)	 mouse	 embryos	 as	 described	 previously	 (Bender	 &	 Weiss,	
2010)(Bender	&	Weiss,	2010)(Bender	and	Weiss	2010).	Briefly,	cells	were	seeded	onto	
poly-L-lysine-coated	tissue	culture	plates,	cultured	in	neurobasal	medium	containing	B-
27	supplement	(Invitrogen),	1%	penicillin-streptomycin,	2	mM	L-glutamine,	and	4	μg/mL	
glutamate	 for	 4	 days	 in	 the	 absence	 of	 an	 astrocyte	 feeder	 layer	 and	 then	 used	 for	
infections.	Neuron	cultures	were	 routinely	95	 to	98%	pure,	 as	determined	by	positive	
immunostaining	 for	MAP2	 and	 negative	 immunostaining	 for	 CD11b	 (microglia-specific	
marker),	 glial	 fibrillary	 acidic	 protein	 (GFAP)	 (astrocyte-specific	 marker),	 and	 OLIG2	
(oligodendrocyte-specific	 marker)	 (Bender,	 Phillips,	 Scott,	 &	 Weiss,	 2010)(Bender,	
Phillips,	 Scott,	 &	 Weiss,	 2010)(Bender,	 Phillips	 et	 al.	 2010).	 (iv)	 Mixed	 glial	 cultures,	
consisting	of	astrocytes	and	microglia,	were	generated	from	the	brains	of	1	to	3-day-old	
neonatal	mice	as	describe	previously	(Zhao	et	al.,	2012;	Zhao,	2012).	Briefly,	tissue	was	
dissociated	by	mechanical	disruption	 through	a	70	µm	nylon	mesh	 filter	and	plated	 in	
complete	medium	 consisting	 of	DMEM	 supplemented	with	 10%	 FBS,	 1%	nonessential	
amino	acid	solution,	2	mM	L-glutamine,	1%	penicillin-streptomycin,	and	10	mM	HEPES	
and	cultured	for	9	to	11	days.	These	cells	were	lifted	from	their	culture	vessel	using	the	
enzyme-free,	Hank’s-based	balanced	salt	 solution	cell	disassociation	buffer	 (Gibco).	 (v)	
Astrocyte	cultures	were	generated	as	described	in	(iv)	and	after	9	to	11	days	in	culture,	
the	 flasks	 were	 shaken	 to	 remove	 nonadherent	 microglial	 cells,	 and	 the	 remaining	
adherent	 cells	were	≥95%	pure	astrocytes,	 as	determined	by	positive	 immunostaining	
for	 GFAP	 (Zhao	 et	 al.,	 2012)(Zhao	 et	 al.,	 2012)(Zhao,	 Jha	 et	 al.	 2012)	 and	 used	 for	
infection.	(vi)	Microglia	cultures	were	generated	from	mixed	glial	cultures	by	collecting	
the	semi-adherent	by	shaking	at	37	˚C	at	300	RPM	for	30	minutes.	(vii)	Mouse	primary	
hepatocytes	were	 isolated	using	 a	 two-step	 collagenase	perfusion	 technique	 involving	
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sequential	 perfusion	 of	 the	 liver	with	 EDTA	 and	 collagenase	 (Invitrogen).	Hepatocytes	
were	plated	on	collagen-coated	plates	(BD	Biosciences)	in	William	E	medium	(Sigma),	a	
modified	MEM	used	 for	 long-term	culture	of	adult	 liver	epithelial	 cells,	 supplemented	
with	10%	 fetal	bovine	 serum	and	antibiotics.	 The	cells	were	allowed	 to	attach	 for	2	h	
before	 switching	 to	 William	 E	 medium	 supplemented	 with	 1%	 (vol/vol)	 nonessential	
amino	acids	(3).	
	
Infections	of	cell	cultures.	Virus	was	added	to	cells	at	a	multiplicity	of	infection	(MOI)	of	
1	PFU/cell	and	allowed	to	adsorb	for	1	hour	at	37	°C.	Cultures	were	washed	with	PBS	(3	
times)	and	 fed	with	medium	as	described	 for	each	cell	 type.	The	culture	supernatants	
were	harvested	at	the	times	indicated	for	the	specific	experiments,	and	the	titers	were	
determined	by	plaque	assay	on	L2	cells.	When	indicated	3T3/pLZ	or	3T3/neo,	cells	were	
treated	with	0	or	100	units/mL	universal	IFN-α	for	4	hours.	Then,	poly(rI):poly(rC)	[pIC],	
(Invitrogen)	 was	 transfected	 at	 a	 concentration	 of	 0	 or	 1	 μg/mL	 using	 0	 or	 3	 μg/mL	
Lipofectamine	 2000	 (Invitrogen)	 according	 to	 the	 manufacturer's	 protocol.	 Mock	
transfected	 cultures	were	maintained	 in	medium	only.	 Cell	 lysates	were	harvested	12	
hours	after	transfection	to	collect	RNA.		
	
IFNAR1	blocking	antibody	treatment.	BMM	cultures	were	treated	with	0,	2,	or	5	µg/mL	
of	IFNAR1	blocking	mAb	(clone	MAR1-5A3,	BD	Sciences)	or	an	isotype	control	(purified	
NA/LE	mouse	IgG1	κ,	clone	107.3,	BD	Sciences)	for	one	hour	at	room	temperature	with	
gentle	agitation	before	virus	infection	or	mock	infection	(Fenner	et	al.,	2006).	
	
Immunoblotting.	Cells	were	treated	with	0	or	100	units/mL	of	universal	 IFNα,	 for	four	
hours	 and	 then	 lysed	 in	 nonidet	 P-40	 (NP-40)	 buffer	 (1%	 NP-40,	 2	 mM	 EDTA,	 10%	
glycerol,	150	mM	NaCl	and	50	mM	Tris	pH	8.0)	containing	protease	inhibitors	(Roche).	
Protein	 concentrations	 were	 measured	 using	 a	 DC	 protein	 assay	 kit	 (Bio-Rad).	
Supernatants	were	mixed	 1:1	with	 2X	 SDS-PAGE	 sample	 buffer.	 Samples	were	 boiled,	
separated	 by	 10%	 SDS-PAGE	 and	 transferred	 to	 polyvinylidene	 difluoride	 (PVDF)	
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membranes.	 Blots	 were	 blocked	 with	 5%	 nonfat	 milk	 and	 probed	 with	 the	 following	
antibodies	 directed	 against:	 OAS1A	 (clone	 E-2,	 Santa	 Cruz;	 1:200),	 OAS2	 (clone	 G-9,	
Santa	 Cruz,	 1:200),	 OAS3	 (clone	 D-7,	 Santa	 Cruz,	 1:200),	mouse	 RNase	 L	 (clone	 T-16,	
Santa	Cruz,	1:200),	mouse	RNase	L	 (rabbit	polyclonal	against	mouse	RNase	L;	1:1000),	
human	RNase	L	(mouse	monoclonal	against	human	RNase	L;	1:1000)	(Dong	&	Silverman,	
1995)	as	well	as	anti-GAPDH-HRP	(Abcam,	1:4000),	anti-β-tubulin-HRP	(Abcam,	1:4000).	
Anti-mouse	 IgG2a-HRP	 (Santa	 Cruz,	 1:4000),	 and	 anti-rabbit	 IgG-HRP	 (GE	 Healthcare,	
1:10000)	 secondary	 antibodies	 were	 used	 to	 detect	 the	 primary	 antibodies	 of	 the	
appropriate	species.	The	blots	were	visualized	using	Super	Signal	West	Dura	Extended	
Duration	 Substrate	 (Thermo	 Scientific).	 In	 Figures	 3.4G	 and	 3.5D	 blots	 were	 probed	
sequentially	with	antibodies	directed	against	OAS1,	OAS2,	OAS3,	RNase	L,	and	GAPDH,	
with	 blots	 being	 stripped	 between	 antibody	 treatments.	 In	 Figures	 3.2D	 and	 3.3B	
parallel	gels	were	run	and	blotted	with	individual	antibodies.	
	
Bioassay	 for	 antiviral	 activity.	 Supernatants	 recovered	 from	 cells	 that	 were	 infected	
with	MHV	strains	at	an	MOI	of	1	PFU/cell	were	exposed	to	600	mJoules•cm-2	UVA	light	
in	 a	 Stratalinker	 1800	 (Stratagene)	 to	 inactivate	 the	 virus.	 L2	mouse	 fibroblasts	 were	
treated	with	the	UV-inactivated	supernatants	for	24	hours	and	then	infected	with	NDV-
GFP	at	an	MOI	of	1	PFU/cell	as	described	previously	(Park	et	al.,	2003)Park,	Shaw	et	al.	
2003).	Control	 cells	were	 treated	with	100	U/mL	universal	 IFNα	 (Quansys	Biosciences,	
UT)	for	24	hours	before	NDV-GFP	infection.	At	12	and	24	hours	post	infection,	cells	were	
fixed	in	Dulbecco’s	phosphate	buffered	saline	(Gibco)	containing	4%	paraformaldehyde	
and	 examined	 for	 enhanced-GFP	 (EGFP)	 expression	 under	 an	 Eclipse	 TE2000-U	
fluorescence	 microscope	 (Nikon	 Instruments,	 Inc.).	 Images	 were	 acquired	 using	 NIS-
Elements	Basic	Research	microscope	imaging	software	(Nikon	Instruments,	Inc.).		
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IFNβ 	quantification.	IFNβ	protein	in	supernatants	of	MHV-infected	BMM	was	quantified	
with	 a	 commercial	 capture	 enzyme-linked	 immunosorbent	 assay	 kit	 (VeriKine	Mouse	
Interferon	 Beta	 ELISA	 Kit,	 PBL	 Laboratories,	 Piscataway,	 NJ)	 according	 to	 the	
manufacturer's	instructions.		
	
Ribosomal	RNA	degradation	assay.	For	quantification	of	rRNA	cleavage,	total	RNA	from	
virus-infected	 cells	 was	 isolated	 using	 an	 RNeasy	 kit	 (Qiagen)	 and	 quantified	 using	 a	
Nanodrop	analyzer.	Equal	amounts	of	RNA	were	separated	on	RNA	chips	and	analyzed	
with	an	Agilent	2100	Bioanalyzer	 (Agilent	Technologies)	as	described	previously	 (Xiang	
et	al.,	2003;	Zhao	et	al.,	2012)(Xiang	et	al.,	2003;	Zhao	et	al.,	2012)(Xiang,	Wang	et	al.	
2003,	Zhao,	Jha	et	al.	2012).		
	
Immunoblotting.	 Cells	 were	 lysed	 in	 nonidet	 P-40	 (NP-40)	 buffer	 (1%	 NP-40,	 2	 mM	
EDTA,	10%	glycerol,	150	mM	NaCl	and	50	mM	Tris	pH	8.0)	containing	protease	inhibitors	
(Roche).	Protein	concentrations	were	measured	using	a	DC	protein	assay	kit	 (Bio-Rad).	
Supernatants	were	mixed	 1:1	with	 2X	 SDS-PAGE	 sample	 buffer.	 Samples	were	 boiled,	
separated	 by	 10%	 SDS-PAGE,	 and	 transferred	 to	 polyvinylidene	 difluoride	 (PVDF)	
membranes.	 Blots	 were	 blocked	 with	 5%	 nonfat	 milk	 and	 probed	 with	 antibodies	
directed	 against	 OAS1A	 (clone	 P-12,	 Santa	 Cruz;	 1:500),	 OAS2	 (ab197655,	 Abcam;	
1:500),	 RNase	 L	 (rabbit	 polyclonal	 against	 mouse	 RNase	 L;	 1:1000),	 RNase	 L	 (mouse	
monoclonal	 against	 human	 RNase	 L;	 1:1000	 (Dong	 &	 Silverman,	 1995)(Dong	 &	
Silverman,	1995)(Dong	and	Silverman	1995)	and	GAPDH-HRP	(ab9385,	Abcam;	1:4000).	
Anti-mouse	HRP	(1:4000	and	anti-rabbit	HRP	(1:10000)	secondary	antibodies	were	used	
accordingly.	The	blots	were	visualized	using	Super	Signal	West	Dura	Extended	Duration	
Substrate	(Thermo	Scientific).		
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Quantifying	 IFNAR1	 surface	 expression.	 BMM	 and	mixed	 glial	 cultures	 were	 stained	
with	antibodies	against	GFAP	(BD,	clone	1B4),	CD11b	(eBioscience,	clone	M1/70),	F4/80	
(Biolegend,	clone	BM8),	and	the	type	I	interferon	receptor	IFNAR1	(Leinco,	clone	MAR1-
5A3)	 or	 an	 isotype	 control	 (Leinco,	 clone	 GIR-208).	 Staining	 for	 GFAP	was	 conducted	
following	permeabilization	with	the	Cytofix/cytoperm	Plus	Fixation/Permeabilization	kit	
(BD).	 Cells	 were	 analyzed	 with	 an	 LSR	 II	 (Becton	 Dickinson)	 and	 resulting	 data	 was	
analyzed	 using	 FlowJo	 Software	 (Treestar).	 Astrocytes	 (GFAP+CD11b-F4/80-)	 and	
microglia	 (GFAP-CD11b+F4/80+)	 from	 mixed	 cultures	 and	 macrophages	 (GFAP-
CD11b+F4/80+)	 from	 bone	 marrow	 derived	 cultures	 were	 assessed	 for	 surface	
expression	of	IFNAR1	(Leinco,	clone	MAR1-5A3)	or	an	isotype	control	(Leinco,	clone	GIR-
208).		
	
Fluorescence	intensity,	dependent	on	both	surface	IFNAR1	density	and	cell	surface	area,	
was	 normalized	 by	 cell	 size	 using	 previously	 described	 methods	 (Knijnenburg	 et	 al.,	
2011).	 This	 allowed	 us	 to	 compare	 receptor	 density	 between	 cells	 of	 different	 sizes.	
Briefly,	 forward	 scatter	 (FSC),	 a	 measure	 of	 cell	 volume,	 and	 side	 scatter	 (SSC),	 a	
measure	 of	 cell	 granularity,	 were	 used	 in	 a	 linear	 least-squares	 regression	 model	 to	
determine	fluorescence	intensities	corrected	for	cell	size	and	shape.	Residuals	from	the	
model	 represent	 the	 variability	 in	 fluorescence	 that	 is	 not	 due	 to	 cell	 size	 and	 cell	
granularity.	 These	 residuals	 were	 offset	 by	 the	 sample-specific	 average	 fluorescence	
intensity	 to	 calculate	 the	 final	 values.	 Calculations	 and	 analysis	 were	 performed	with	
MATLAB	(Mathworks,	Natick,	MD).	
	
Statistical	 analysis.	 Plotting	 of	 data	 and	 statistical	 analysis	 were	 performed	 using	
GraphPad	 Prism	 software	 (GraphPad	 Software,	 Inc.,	 CA)	 Statistical	 significance	 was	
determined	by	the	unpaired	two-tailed	Student's	t	test.		
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